Suresh S. Ramalingam, MD, FACP, FASCO

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (44 ratings)

Role

Medical Oncology
Specialty

Lung Cancer
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2003

Call 404-778-1900

Biography

Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer.

Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar.

Play Video

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine
Roberto C. Goizueta Distinguished Chair for Cancer Research

Emory University School of Medicine
Executive Director

Winship Cancer Institute of Emory University
Associate Vice President for Cancer

Woodruff Health Sciences Center

Education & Training

Education

Fellowship, Hematology & Oncology, 2003
University of Pittsburgh Medical Center
Residency, Internal Medicine, 1996
Wayne State University
Internship, Internal Medicine, 1994
Wayne State University
Medical Education, MBBS, 1992
Kilpauk Medical College

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2003

Professional Memberships

Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.

Research

Dr. Ramalingam's present research involves developing immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation.

Clinical Trials

Dr. Ramalingam has conducted several phase 1, 2 and 3 clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer.

View Current Clinical Trials


Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations Phase III Conditions Non-Small Cell Lung Cancer Location Winship Cancer Institute
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Phase I Conditions Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation Location Winship Cancer Institute

Grants

View Grants

Grant Number	Title
1P01CA257906-01A1	Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
2P30CA138292-14	Winship Cancer Institute Cancer Center Support Grant
3P30CA138292-14S1	Administrative Supplement: Population-Based Study of Social Determinants of Health and Quality of Cancer Care in HIV-Associated Cancers
3P30CA138292-14S2	Administrative Supplement: Enhance the Utility of Data Available through the Childhood Cancer Data Initiative (CCDI) Ecosystem
3P30CA138292-14S3	Administrative Supplement: Cervical Cancer Recurrence and the Vaginal Microbiome
3P30CA138292-15S1	Administrative Supplement: Early Career Cancer Clinical Investigator Award (ECIA)
3P30CA138292-15S2	Administrative Supplement: Assessing and Enhancing Survivorship Care
3P50CA217691-05S1	Administrative Supplement: Interim Funding for Emory Lung Cancer SPORE
5K12CA237806-05	Emory Clinical Oncology Career Development Award K12 Program
5P01CA257906-02	Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
5P01CA257906-03	Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
5P30CA138292-15	Winship Cancer Institute Cancer Center Support Grant
5P50CA217691-05	Emory University Lung Cancer SPORE

Publications

Dr. Ramalingam has authored over 300 scientific publications. He serves as editor-in-chief of CANCER, a peer-reviewed journal of the American Cancer Society.

Title/Journal	Authors	Publication Date
EGFR mutation testing across the osimertinib clinical program. Lung cancer (Amsterdam, Netherlands)	ML Murat-Onana, SS Ramalingam, PA Jänne, JE Gray, MJ Ahn, T John, Y Yatabe, X Huang, Y Rukazenkov, M Javey, H Brown, X Li-Sucholeiki	04/18/2025
Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells. Oncogene	YT Oh, Z Chen, D Wang, SS Ramalingam, SY Sun	04/17/2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial. Advances in therapy	HD Hummel, MJ Ahn, F Blackhall, M Reck, H Akamatsu, SS Ramalingam, H Borghaei, M Johnson, F Dirnberger, K Cocks, S Huang, S Mukherjee, L Paz-Ares	04/01/2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. Future oncology (London, England)	AJ de Langen, ML Johnson, J Mazieres, AC Dingemans, G Mountzios, M Pless, J Wolf, M Schuler, H Lena, F Skoulidis, Y Yoneshima, SW Kim, H Linardou, S Novello, AJ van der Wekken, Y Chen, S Peters, E Felip, BJ Solomon, SS Ramalingam, C Dooms, CR Lindsay, CG Ferreira, N Blais, CC Obiozor, Y Wang, B Mehta, T Varrieur, G Ngarmchamnanrith, B Stollenwerk, D Waterhouse, L Paz-Ares	04/01/2025
A Response to the Letter to the Editor: "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC". Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	JW Carlisle, RD Pentz, SS Ramalingam	04/01/2025
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung cancer (Amsterdam, Netherlands)	MC Garassino, Y He, MJ Ahn, SV Orlov, V Potter, T Kato, J Laskin, PJ Voon, T Reungwetwattana, SS Ramalingam, YL Wu, M Albayaty, SL Cross, X Huang, D Kulkarni, BC Cho	04/01/2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer. The oncologist	MS von Itzstein, S Rashdan, SE Dahlberg, DE Gerber, AB Sandler, JH Schiller, DH Johnson, Y Wang, Z Sun, SS Ramalingam	03/10/2025
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer. Nature communications	C Shu, J Li, J Rui, D Fan, Q Niu, R Bai, D Cicka, S Doyle, A Wahafu, X Zheng, Y Du, AA Ivanov, DB Doxie, KM Dhodapkar, J Carlisle, T Owonikoko, G Sica, Y Liu, S Ramalingam, MV Dhodapkar, W Zhou, X Mo, H Fu	03/08/2025
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT). Lung cancer (Amsterdam, Netherlands)	C Gridelli, T Mok, P Jänne, A Passaro, E Felip, SS Ramalingam, I Attili, F de Marinis	03/01/2025
The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. The oncologist	NT Sebastian, WA Stokes, M Behera, R Jiang, DA Gutman, Z Huang, A Burns, V Sukhatme, MC Lowe, SS Ramalingam, VP Sukhatme, D Moghanaki	02/06/2025
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking. Lung cancer (Amsterdam, Netherlands)	JE Reuss, J Zaemes, N Gandhi, P Walker, SP Patel, J Xiu, C Aggarwal, A Vanderwalde, SS Ramalingam, B Halmos, SV Liu	02/01/2025
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nature reviews. Clinical oncology	F Zhou, H Guo, Y Xia, X Le, DSW Tan, SS Ramalingam, C Zhou	02/01/2025
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	S Peters, LG Paz-Ares, M Reck, DP Carbone, JR Brahmer, H Borghaei, S Lu, KJ O'Byrne, T John, TE Ciuleanu, M Schenker, R Bernabe Caro, M Nishio, M Cobo, JS Lee, B Zurawski, A Pluzanski, T Aoyama, M Tschaika, V Devas, DJ Grootendorst, SS Ramalingam	01/01/2025
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer. The oncologist	J Shaw, X Pundole, A Balasubramanian, ES Anderson, M Pastel, DG Bebb, T Jiang, P Martinez, SS Ramalingam, H Borghaei	12/06/2024
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study. Annals of oncology : official journal of the European Society for Medical Oncology	S Lu, MJ Ahn, T Reungwetwattana, M Özgüroğlu, T Kato, JC Yang, M Huang, F Fujiki, T Inoue, LV Quang, V Sriuranpong, D Vicente, C Fuentes, AA Chaudhry, L Poole, E Armenteros Monterroso, Y Rukazenkov, T van der Gronde, SS Ramalingam	12/01/2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer. Future oncology (London, England)	MJ Ahn, BC Cho, E Felip, I Korantzis, K Ohashi, M Majem, O Juan-Vidal, S Handzhiev, H Izumi, JS Lee, R Dziadziuszko, J Wolf, F Blackhall, M Reck, JB Alvarez, HD Hummel, AC Dingemans, J Sands, H Akamatsu, TK Owonikoko, SS Ramalingam, H Borghaei, ML Johnson, S Huang, S Mukherjee, M Minocha, T Jiang, P Martinez, ES Anderson, L Paz-Ares	12/01/2024
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export. Nature cancer	BK Tripathi, NH Hirsh, X Qian, ME Durkin, D Wang, AG Papageorge, R Lake, YA Evrard, AI Marcus, SS Ramalingam, M Dasso, KH Vousden, JH Doroshow, KJ Walters, DR Lowy	12/01/2024
Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer. Cancer research	J Koo, CS Seong, RE Parker, A Herrera, B Dwivedi, RA Arthur, AR Dinasarapu, HR Johnston, H Claussen, C Tucker-Burden, SS Ramalingam, H Fu, W Zhou, AI Marcus, M Gilbert-Ross	11/15/2024
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. The Journal of experimental medicine	Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun	11/04/2024
Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections. Clinical lung cancer	M Somisetty, PC Mack, CY Hsu, Y Huang, JE Gomez, AM Rodilla, J Cagan, SC Tavolacci, JM Carreño, R Brody, AC Moore, JC King, NC Rohs, C Rolfo, PA Bunn, JD Minna, S Bhalla, F Krammer, A García-Sastre, JC Figueiredo, E Kazemian, KL Reckamp, AA Merchant, M Nadri, R Ahmed, SS Ramalingam, Y Shyr, FR Hirsch, DE Gerber	11/01/2024
Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	JW Carlisle, RD Pentz, SS Ramalingam	11/01/2024
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	JE Gray, A Markovets, T Reungwetwattana, M Majem, N Nogami, N Peled, JS Lee, BC Cho, B Chewaskulyong, T John, JY Han, M Sebastian, A Todd, Y Rukazenkov, C Barrett, J Chmielecki, SM Lee, SS Ramalingam, R Hartmaier	11/01/2024
The MARIPOSA trials - implications for the treatment of EGFR-mutant NSCLC. Nature reviews. Clinical oncology	F Ardeshir-Larijani, SS Ramalingam	11/01/2024
Spatially resolved subcellular protein-protein interactomics in drug-perturbed lung-cancer cultures and tissues. Nature biomedical engineering	S Cai, T Hu, A Venkataraman, FG Rivera Moctezuma, E Ozturk, N Zhang, M Wang, T Zvidzai, S Das, A Pillai, F Schneider, SS Ramalingam, YT Oh, SY Sun, AF Coskun	10/30/2024
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. Reply. The New England journal of medicine	S Lu, SS Ramalingam	10/24/2024
Direct to Cancer: A new initiative to enhance the author experience. Cancer	SS Ramalingam, CA Gilman	10/15/2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology. Lung cancer (Amsterdam, Netherlands)	JA Marks, N Gandhi, B Halmos, ME Marmarelis, S Yeon Kim, L Bazhenova, SS Ramalingam, J Xiu, P Walker, MJ Oberley, PC Ma, SV Liu	10/01/2024
Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany)	Z Chen, KA Vallega, VK Boda, Z Quan, D Wang, S Fan, Q Wang, SS Ramalingam, W Li, SY Sun	09/01/2024
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. The New England journal of medicine	S Lu, T Kato, X Dong, MJ Ahn, LV Quang, N Soparattanapaisarn, T Inoue, CL Wang, M Huang, JC Yang, M Cobo, M Özgüroğlu, I Casarini, DV Khiem, V Sriuranpong, E Cronemberger, T Takahashi, Y Runglodvatana, M Chen, X Huang, E Grainger, D Ghiorghiu, T van der Gronde, SS Ramalingam	08/15/2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial. JTO clinical and research reports	BJ Solomon, I Dagogo-Jack, SH Lee, MJ Boyer, SS Ramalingam, E Carcereny, E Felip, JY Han, T Hida, BGM Hughes, SW Kim, M Nishio, T Seto, T Okamoto, X Zhang, JF Martini, E Wang, S De Beukelaer, TM Bauer	07/01/2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study. Lung cancer (Amsterdam, Netherlands)	H Borghaei, X Pundole, L Sangaré, E Anderson, DG Bebb, T Jiang, M Pastel, G Carrigan, A Balasubramanian, P Martinez, SS Ramalingam	07/01/2024
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best. Cancer	TA Leal, SS Ramalingam	06/01/2024
Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ Study. JTO clinical and research reports	M Behera, R Jiang, Z Huang, B Bunn, MW Wynes, J Switchenko, GV Scagliotti, CP Belani, SS Ramalingam	06/01/2024
Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research	A Mariniello, TH Nasti, DY Chang, M Hashimoto, S Malik, DT McManus, J Lee, DJ McGuire, MA Cardenas, P Umana, V Nicolini, R Antia, A Saha, Z Buchwald, H Kissick, E Ghorani, S Novello, D Sangiolo, GV Scagliotti, SS Ramalingam, R Ahmed	05/01/2024
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer. The oncologist	DE Gerber, Y Wang, SS Ramalingam, S Bhalla, Z Sun, H Borghaei, JR Brahmer, JH Schiller	04/04/2024
Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy. Trends in cancer	M Hashimoto, SS Ramalingam, R Ahmed	04/01/2024
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. The Journal of clinical investigation	Z Chen, KA Vallega, D Wang, Z Quan, S Fan, Q Wang, T Leal, SS Ramalingam, SY Sun	03/07/2024
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer. Clinical pharmacology and therapeutics	M Johnson, C Serra Traynor, K Vishwanathan, P Overend, R Hartmaier, A Markovets, J Chmielecki, GM Mugundu, JC Barrett, H Tomkinson, SS Ramalingam	02/01/2024
Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy. BMJ oncology	RC Obeng, TH Nasti, K Martens, P Li, A Mariniello, DY Chang, CS Eberhardt, D McGuire, H Kissick, C Daugherty, Y Zhang, A Wieland, Z Chen, JM Switchenko, R Pillai, AO Kamphorst, WJ Leonard, R Ahmed, SS Ramalingam	01/01/2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer. Future oncology (London, England)	GJ Riely, EF Smit, MJ Ahn, E Felip, SS Ramalingam, A Tsao, M Johnson, F Gelsomino, R Esper, E Nadal, M Offin, M Provencio, J Clarke, M Hussein, GA Otterson, I Dagogo-Jack, JW Goldman, D Morgensztern, A Alcasid, T Usari, P Wissel, K Wilner, N Pathan, S Tonkovyd, BE Johnson	01/01/2024
Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study. Future oncology (London, England)	SS Ramalingam, JW Carlisle	01/01/2024
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary. Future oncology (London, England)	GK Dy, R Govindan, V Velcheti, GS Falchook, A Italiano, J Wolf, AG Sacher, T Takahashi, SS Ramalingam, C Dooms, DW Kim, A Addeo, J Desai, M Schuler, P Tomasini, DS Hong, P Lito, Q Tran, S Jones, A Anderson, A Hindoyan, W Snyder, F Skoulidis, BT Li	01/01/2024
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives. Lung cancer (Amsterdam, Netherlands)	T Kato, I Casarini, M Cobo, C Faivre-Finn, F Hegi-Johnson, S Lu, M Özgüroğlu, SS Ramalingam	01/01/2024
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic. The Journal of molecular diagnostics : JMD	JE Gray, JY Han, A Telaranta-Keerie, X Huang, A Kohlmann, R Hodge, Y Rukazenkov, J Chmielecki, CR Espenschied, M Lefterova, YL Wu, SS Ramalingam, JC Barrett, JI Odegaard	01/01/2024
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer. Cancer	NS McCall, JR Janopaul-Naylor, HS McGinnis, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, TA Leal, SS Ramalingam, JD Bradley, KA Higgins	12/01/2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial. ESMO open	H Borghaei, KJ O'Byrne, L Paz-Ares, TE Ciuleanu, X Yu, A Pluzanski, A Nagrial, L Havel, RD Kowalyszyn, CA Valette, JR Brahmer, M Reck, SS Ramalingam, L Zhang, I Ntambwe, SK Rabindran, FE Nathan, D Balli, YL Wu	12/01/2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. The New England journal of medicine	MJ Ahn, BC Cho, E Felip, I Korantzis, K Ohashi, M Majem, O Juan-Vidal, S Handzhiev, H Izumi, JS Lee, R Dziadziuszko, J Wolf, F Blackhall, M Reck, J Bustamante Alvarez, HD Hummel, AC Dingemans, J Sands, H Akamatsu, TK Owonikoko, SS Ramalingam, H Borghaei, ML Johnson, S Huang, S Mukherjee, M Minocha, T Jiang, P Martinez, ES Anderson, L Paz-Ares	11/30/2023
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer. NPJ vaccines	RM Valanparambil, L Lai, MA Johns, M Davis-Gardner, SL Linderman, TO McPherson, A Chang, A Akhtar, ELB Gamarra, H Matia, AA McCook-Veal, J Switchenko, TH Nasti, F Green, M Saini, A Wieland, BA Pinsky, D Solis, MV Dhodapkar, J Carlisle, S Ramalingam, R Ahmed, MS Suthar	11/21/2023
Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer. Cancer cell	AM Rodilla, RM Valanparambil, PC Mack, CY Hsu, J Cagan, SC Tavolacci, JM Carreño, R Brody, A Moore, JC King, JE Gomez, N Rohs, C Rolfo, PA Bunn, DE Gerber, JD Minna, F Krammer, SS Ramalingam, A García-Sastre, Y Shyr, R Ahmed, FR Hirsch	11/13/2023
Characteristics and anatomic location of PD-1⁺TCF1⁺ stem-like CD8 T cells in chronic viral infection and cancer. Proceedings of the National Academy of Sciences of the United States of America	SJ Im, RC Obeng, TH Nasti, D McManus, AO Kamphorst, S Gunisetty, N Prokhnevska, JW Carlisle, K Yu, GL Sica, LE Cardozo, ANA Gonçalves, HT Kissick, HI Nakaya, SS Ramalingam, R Ahmed	10/10/2023
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA. Clinical cancer research : an official journal of the American Association for Cancer Research	JE Gray, MJ Ahn, GR Oxnard, FA Shepherd, F Imamura, Y Cheng, I Okamoto, BC Cho, MC Lin, YL Wu, M Majem, O Gautschi, M Boyer, KC Bulusu, A Markovets, JC Barrett, R Hodge, A McKeown, RJ Hartmaier, J Chmielecki, VA Papadimitrakopoulou, SS Ramalingam	09/01/2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	M Reck, TE Ciuleanu, JS Lee, M Schenker, B Zurawski, SW Kim, M Mahave, A Alexandru, S Peters, A Pluzanski, RB Caro, H Linardou, JA Burgers, M Nishio, A Martinez-Marti, K Azuma, R Axelrod, LG Paz-Ares, SS Ramalingam, H Borghaei, KJ O'Byrne, L Li, J Bushong, RG Gupta, DJ Grootendorst, LJ Eccles, JR Brahmer	08/01/2023
Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report. JTO clinical and research reports	R Thummalapalli, NJ Choudhury, F Ehrich, T Beardslee, D Brazel, SS Zhang, S Merchant, MF Chen, G Heller, SS Ramalingam, SI Ou, KF Mileham, GJ Riely	08/01/2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF^V600-Mutant Metastatic Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	GJ Riely, EF Smit, MJ Ahn, E Felip, SS Ramalingam, A Tsao, M Johnson, F Gelsomino, R Esper, E Nadal, M Offin, M Provencio, J Clarke, M Hussain, GA Otterson, I Dagogo-Jack, JW Goldman, D Morgensztern, A Alcasid, T Usari, P Wissel, K Wilner, N Pathan, S Tonkovyd, BE Johnson	07/20/2023
Cancer Turns 75! Cancer	SS Ramalingam	07/01/2023
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	GK Dy, R Govindan, V Velcheti, GS Falchook, A Italiano, J Wolf, AG Sacher, T Takahashi, SS Ramalingam, C Dooms, DW Kim, A Addeo, J Desai, M Schuler, P Tomasini, DS Hong, P Lito, Q Tran, S Jones, A Anderson, A Hindoyan, W Snyder, F Skoulidis, BT Li	06/20/2023
Live-cell invasive phenotyping uncovers the ALK2/BMP6 iron homeostasis pathway as a therapeutic vulnerability in LKB1-mutant lung cancer. bioRxiv : the preprint server for biology	J Koo, CS Seong, RE Parker, B Dwivedi, RA Arthur, AR Dinasarapu, HR Johnston, H Claussen, C Tucker-Burden, SS Ramalingam, H Fu, W Zhou, AI Marcus, M Gilbert-Ross	06/14/2023
The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical lung cancer	NT Sebastian, WA Stokes, M Behera, R Jiang, DA Gutman, Z Huang, A Burns, V Sukhatme, MC Lowe, SS Ramalingam, VP Sukhatme, D Moghanaki	05/01/2023
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	DW Kim, SW Kim, DR Camidge, CA Shu, KA Marrone, X Le, CM Blakely, K Park, GC Chang, SP Patel, G Kar, ZA Cooper, R Samadani, M Pluta, R Kumar, S Ramalingam	05/01/2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS^G12C mutation: a randomised, open-label, phase 3 trial. Lancet (London, England)	AJ de Langen, ML Johnson, J Mazieres, AC Dingemans, G Mountzios, M Pless, J Wolf, M Schuler, H Lena, F Skoulidis, Y Yoneshima, SW Kim, H Linardou, S Novello, AJ van der Wekken, Y Chen, S Peters, E Felip, BJ Solomon, SS Ramalingam, C Dooms, CR Lindsay, CG Ferreira, N Blais, CC Obiozor, Y Wang, B Mehta, T Varrieur, G Ngarmchamnanrith, B Stollenwerk, D Waterhouse, L Paz-Ares	03/04/2023
Engagement and outcomes of cancer patients referred to a tobacco cessation program at a National Cancer Institute-designated cancer center. Cancer medicine	SA Westergaard, M Rupji, LE Franklin, M Behera, SS Ramalingam, KA Higgins	03/01/2023
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies. Targeted oncology	S Popat, MJ Ahn, S Ekman, NB Leighl, SS Ramalingam, T Reungwetwattana, S Siva, M Tsuboi, YL Wu, JC Yang	03/01/2023
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nature communications	J Chmielecki, T Mok, YL Wu, JY Han, MJ Ahn, SS Ramalingam, T John, I Okamoto, JC Yang, FA Shepherd, KC Bulusu, G Laus, B Collins, JC Barrett, RJ Hartmaier, V Papadimitrakopoulou	02/27/2023
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature communications	J Chmielecki, JE Gray, Y Cheng, Y Ohe, F Imamura, BC Cho, MC Lin, M Majem, R Shah, Y Rukazenkov, A Todd, A Markovets, JC Barrett, RJ Hartmaier, SS Ramalingam	02/27/2023
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. Annals of oncology : official journal of the European Society for Medical Oncology	H Borghaei, TE Ciuleanu, JS Lee, A Pluzanski, RB Caro, M Gutierrez, Y Ohe, M Nishio, J Goldman, N Ready, DR Spigel, SS Ramalingam, LG Paz-Ares, JF Gainor, S Ahmed, M Reck, M Maio, KJ O'Byrne, A Memaj, F Nathan, P Tran, MD Hellmann, JR Brahmer	02/01/2023
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis. bioRxiv : the preprint server for biology	CS Seong, C Huang, AC Boese, Y Hou, J Koo, JK Mouw, M Rupji, G Joseph, HR Johnston, H Claussen, JM Switchenko, M Behera, M Churchman, JM Kolesar, SM Arnold, K Kerrigan, W Akerley, H Colman, MA Johns, C Arciero, W Zhou, AI Marcus, SS Ramalingam, H Fu, M Gilbert-Ross	01/27/2023
mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection. The Journal of clinical investigation	S Ando, CM Perkins, Y Sajiki, C Chastain, RM Valanparambil, A Wieland, WH Hudson, M Hashimoto, SS Ramalingam, GJ Freeman, R Ahmed, K Araki	01/17/2023
Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancer. Cancer medicine	WA Stokes, M Behera, R Jiang, DA Gutman, Z Huang, A Burns, NT Sebastian, V Sukhatme, MC Lowe, SS Ramalingam, VP Sukhatme, D Moghanaki	01/01/2023
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer. Expert review of anticancer therapy	JC Yang, C Zhou, PA Jänne, SS Ramalingam, TM Kim, GJ Riely, AI Spira, Z Piotrowska, T Mekhail, MR Garcia Campelo, E Felip, L Bazhenova, S Jin, M Kaur, PM Diderichsen, N Gupta, V Bunn, J Lin, E N Churchill, M Mehta, D Nguyen	01/01/2023
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	LG Paz-Ares, TE Ciuleanu, A Pluzanski, JS Lee, JF Gainor, GA Otterson, C Audigier-Valette, N Ready, M Schenker, H Linardou, RB Caro, M Provencio, B Zurawski, KH Lee, SW Kim, C Caserta, SS Ramalingam, DR Spigel, JR Brahmer, M Reck, KJ O'Byrne, N Girard, S Popat, S Peters, A Memaj, F Nathan, N Aanur, H Borghaei	01/01/2023
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies. Targeted oncology	S Popat, MJ Ahn, S Ekman, NB Leighl, SS Ramalingam, T Reungwetwattana, S Siva, M Tsuboi, YL Wu, JC Yang	01/01/2023
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort. Journal of clinical medicine	MR Garcia Campelo, C Zhou, SS Ramalingam, HM Lin, TM Kim, GJ Riely, T Mekhail, D Nguyen, E Goodman, M Mehta, S Popat, PA Jänne	12/23/2022
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell reports	J Kang, J Chun, JS Hwang, C Pan, J Li, AC Boese, I Young, CM Malin, Y Kang, DL Gibbons, G Sica, H Fu, SS Ramalingam, L Jin, S Kang	12/13/2022
Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RM Valanparambil, J Carlisle, SL Linderman, A Akthar, RL Millett, L Lai, A Chang, AA McCook-Veal, J Switchenko, TH Nasti, M Saini, A Wieland, KE Manning, M Ellis, KM Moore, SL Foster, K Floyd, ME Davis-Gardner, VV Edara, M Patel, C Steur, AK Nooka, F Green, MA Johns, F O'Brein, U Shanmugasundaram, VI Zarnitsyna, H Ahmed, LE Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, MS Suthar, MV Dhodapkar, S Ramalingam, R Ahmed	11/20/2022
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. Cancer gene therapy	Y Deng, G Ma, KA Vallega, D Wang, M Wang, C Wang, S Wang, SS Ramalingam, SY Sun	11/01/2022
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1. Cancer gene therapy	Y Deng, G Ma, KA Vallega, D Wang, M Wang, C Wang, S Wang, SS Ramalingam, SY Sun	11/01/2022
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Clinical lung cancer	BE Osta, J Carlisle, C Steuer, S Pakkala, T Leal, M Dhodapkar, Y Liu, Z Chen, T Owonikoko, S Ramalingam	11/01/2022
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clinical lung cancer	JM Varlotto, Z Sun, B Ky, J Upshaw, TJ Fitzgerald, M Diehn, C Lovly, C Belani, K Oettel, G Masters, M Harkenrider, H Ross, S Ramalingam, NA Pennell	11/01/2022
PD-1 combination therapy with IL-2 modifies CD8⁺ T cell exhaustion program. Nature	M Hashimoto, K Araki, MA Cardenas, P Li, RR Jadhav, HT Kissick, WH Hudson, DJ McGuire, RC Obeng, A Wieland, J Lee, DT McManus, JL Ross, SJ Im, J Lee, JX Lin, B Hu, EE West, CD Scharer, GJ Freeman, AH Sharpe, SS Ramalingam, A Pellerin, V Teichgräber, WJ Greenleaf, C Klein, JJ Goronzy, P Umaña, WJ Leonard, KA Smith, R Ahmed	10/01/2022
Multiplexed protein profiling reveals spatial subcellular signaling networks. iScience	S Cai, T Hu, M Venkatesan, M Allam, F Schneider, SS Ramalingam, SY Sun, AF Coskun	09/16/2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for immunotherapy of cancer	MB Atkins, H Abu-Sbeih, PA Ascierto, MR Bishop, DS Chen, M Dhodapkar, LA Emens, MS Ernstoff, RL Ferris, TF Greten, JL Gulley, RS Herbst, RW Humphrey, J Larkin, KA Margolin, L Mazzarella, SS Ramalingam, MM Regan, BI Rini, M Sznol	09/01/2022
Spatially variant immune infiltration scoring in human cancer tissues. NPJ precision oncology	M Allam, T Hu, J Lee, J Aldrich, SS Badve, Y Gökmen-Polar, M Bhave, SS Ramalingam, F Schneider, AF Coskun	09/01/2022
Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	NS McCall, HS McGinnis, JR Janopaul-Naylor, AH Kesarwala, S Tian, WA Stokes, JW Shelton, CE Steuer, JW Carlisle, T Leal, SS Ramalingam, JD Bradley, KA Higgins	09/01/2022
MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. The Journal of clinical investigation	D Yan, JM Huelse, D Kireev, Z Tan, L Chen, S Goyal, X Wang, SV Frye, M Behera, F Schneider, SS Ramalingam, T Owonikoko, HS Earp, D DeRyckere, DK Graham	08/01/2022
Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	TA Leal, SE Dahlberg, SS Ramalingam	07/20/2022
Neoadjuvant therapy gains FDA approval in non-small cell lung cancer. Cell reports. Medicine	TA Leal, SS Ramalingam	07/19/2022
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO clinical and research reports	AJ Piper-Vallillo, JK Rotow, JV Aredo, K Shaverdashvili, J Luo, JW Carlisle, H Husain, A Muzikansky, RS Heist, D Rangachari, SS Ramalingam, HA Wakelee, HA Yu, LV Sequist, JM Bauml, JW Neal, Z Piotrowska	06/01/2022
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. Cell	X Mo, Q Niu, AA Ivanov, YH Tsang, C Tang, C Shu, Q Li, K Qian, A Wahafu, SP Doyle, D Cicka, X Yang, D Fan, MA Reyna, LAD Cooper, CS Moreno, W Zhou, TK Owonikoko, S Lonial, FR Khuri, Y Du, SS Ramalingam, GB Mills, H Fu	05/26/2022
Distinct phenotypic states and spatial distribution of CD8⁺ T cell clonotypes in human brain metastases. Cell reports. Medicine	LJ Sudmeier, KB Hoang, EK Nduom, A Wieland, SG Neill, MJ Schniederjan, SS Ramalingam, JJ Olson, R Ahmed, WH Hudson	05/17/2022
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clinical lung cancer	D De Ruysscher, S Ramalingam, J Urbanic, DE Gerber, DSW Tan, J Cai, A Li, S Peters	05/01/2022
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA oncology	KL Kehl, D Zahrieh, P Yang, SL Hillman, AD Tan, JM Sands, GR Oxnard, EA Gillaspie, D Wigle, S Malik, TE Stinchcombe, SS Ramalingam, K Kelly, R Govindan, SJ Mandrekar, RU Osarogiagbon, D Kozono	05/01/2022
Impact of Workforce Challenges and Funds Flow on Cancer Clinical Trial Development and Conduct. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	NA Pennell, C Szczepanek, D Spigel, SS Ramalingam	04/01/2022
Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs. Chest	YA Syed, W Stokes, M Rupji, Y Liu, O Khullar, N Sebastian, K Higgins, JD Bradley, WJ Curran, S Ramalingam, J Taylor, M Sancheti, F Fernandez, D Moghanaki	03/01/2022
Encorafenib plus binimetinib in patients with BRAF^V600-mutant non-small cell lung cancer: phase II PHAROS study design. Future oncology (London, England)	GJ Riely, MJ Ahn, E Felip, SS Ramalingam, EF Smit, AS Tsao, A Alcasid, T Usari, PS Wissel, KD Wilner, BE Johnson	03/01/2022
Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC. JTO clinical and research reports	JM Varlotto, Y Wang, Z Sun, HA Wakelee, S Ramalingam, J Schiller	03/01/2022
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. Oncogene	G Ma, Y Deng, L Qian, KA Vallega, G Zhang, X Deng, TK Owonikoko, SS Ramalingam, DD Fang, Y Zhai, SY Sun	03/01/2022
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	LG Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee, L Urban, RB Caro, K Park, H Sakai, Y Ohe, M Nishio, C Audigier-Valette, JA Burgers, A Pluzanski, R Sangha, C Gallardo, M Takeda, H Linardou, L Lupinacci, KH Lee, C Caserta, M Provencio, E Carcereny, GA Otterson, M Schenker, B Zurawski, A Alexandru, A Vergnenegre, J Raimbourg, K Feeney, SW Kim, H Borghaei, KJ O'Byrne, MD Hellmann, A Memaj, FE Nathan, J Bushong, P Tran, JR Brahmer, M Reck	02/01/2022
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ open	PS Kok, PM Forde, B Hughes, Z Sun, C Brown, S Ramalingam, A Cook, WJ Lesterhuis, S Yip, K O'Byrne, N Pavlakis, J Brahmer, V Anagnostou, K Ford, K Fitzpatrick, A Bricker, MM Cummins, M Stockler, AK Nowak	01/25/2022
Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern. medRxiv : the preprint server for health sciences	R Valanparambil, J Carlisle, S Linderman, A Akthar, RL Millett, L Lai, A Chang, A McCook, J Switchenko, T Nasti, M Saini, AW Andreas Wieland, K Manning, M Ellis, K Moore, S Foster, K Floyd, M Davis-Gardner, V Viswanadh Edara, M Patel, C Steur, A Nooka, F Green, M Johns, F O Brein, U Shanmugasundaram, V Zarnitsyna, H Ahmed, L Nyhoff, G Mantus, M Garett, S Edupuganti, M Behra, R Antia, J Wrammert, M Suthar, M Dhodapkar, S Ramalingam, R Ahmed	01/23/2022
The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells. American journal of cancer research	C Liu, L Qian, KA Vallega, G Ma, D Zong, L Chen, S Wang, SR Ramalingam, Z Qin, SY Sun	01/01/2022
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer	SS Ramalingam, E Thara, MM Awad, A Dowlati, B Haque, TE Stinchcombe, GK Dy, DR Spigel, S Lu, N Iyer Singh, Y Tang, I Teslenko, N Iannotti	01/01/2022
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. Frontiers in immunology	DS Hong, AK Gopal, AN Shoushtari, SP Patel, AR He, T Doi, SS Ramalingam, A Patnaik, S Sandhu, Y Chen, CB Davis, TS Fisher, B Huang, KD Fly, A Ribas	01/01/2022
The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. Pharmacological research	Z Chen, KA Vallega, H Chen, J Zhou, SS Ramalingam, SY Sun	01/01/2022
The National Cancer Act of 1971: A seminal milestone in the fight against cancer. Cancer	SS Ramalingam, FR Khuri	12/15/2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA oncology	C Zhou, SS Ramalingam, TM Kim, SW Kim, JC Yang, GJ Riely, T Mekhail, D Nguyen, MR Garcia Campelo, E Felip, S Vincent, S Jin, C Griffin, V Bunn, J Lin, HM Lin, M Mehta, PA Jänne	12/01/2021
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene	Z Chen, D Yu, TK Owonikoko, SS Ramalingam, SY Sun	12/01/2021
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, S Novello, SZ Guclu, D Bentsion, Z Zvirbule, M Szilasi, R Bernabe, K Syrigos, LA Byers, P Clingan, J Bar, EE Vokes, R Govindan, M Dunbar, P Ansell, L He, X Huang, V Sehgal, J Glasgow, BA Bach, J Mazieres	11/10/2021
Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer. JCO oncology practice	CE Steuer, SS Ramalingam	11/01/2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nature medicine	PM Forde, V Anagnostou, Z Sun, SE Dahlberg, HL Kindler, N Niknafs, T Purcell, R Santana-Davila, AZ Dudek, H Borghaei, M Lanis, Z Belcaid, KN Smith, A Balan, JR White, C Cherry, IK Ashok Sivakumar, XM Shao, HY Chan, D Singh, S Thapa, PB Illei, DM Pardoll, R Karchin, VE Velculescu, JR Brahmer, SS Ramalingam	11/01/2021
Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. Cancer letters	W Zhao, D Yu, Z Chen, W Yao, J Yang, SS Ramalingam, SY Sun	10/28/2021
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular cancer research : MCR	G Qian, J Guo, KA Vallega, C Hu, Z Chen, Y Deng, Q Wang, S Fan, SS Ramalingam, TK Owonikoko, W Wei, SY Sun	10/01/2021
Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib. Cancer research	L Zhu, Z Chen, H Zang, S Fan, J Gu, G Zhang, KD Sun, Q Wang, Y He, TK Owonikoko, SS Ramalingam, SY Sun	09/15/2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA oncology	SN Gettinger, MW Redman, L Bazhenova, FR Hirsch, PC Mack, LH Schwartz, JD Bradley, TE Stinchcombe, NB Leighl, SS Ramalingam, SS Tavernier, H Yu, JM Unger, K Minichiello, L Highleyman, VA Papadimitrakopoulou, K Kelly, DR Gandara, RS Herbst	09/01/2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for immunotherapy of cancer	NB Leighl, MW Redman, N Rizvi, FR Hirsch, PC Mack, LH Schwartz, JL Wade, WJ Irvin, SC Reddy, J Crawford, JD Bradley, TE Stinchcombe, SS Ramalingam, J Miao, K Minichiello, RS Herbst, VA Papadimitrakopoulou, K Kelly, DR Gandara	08/01/2021
Cancer matters: Now more than ever! Cancer	SS Ramalingam	07/01/2021
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress. Clinical lung cancer	S Lu, I Casarini, T Kato, M Cobo, M Özgüroğlu, R Hodge, T van der Gronde, M Saggese, SS Ramalingam	07/01/2021
Sotorasib for Lung Cancers with KRAS p.G12C Mutation. The New England journal of medicine	F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, M Schuler, H Borghaei, F Barlesi, T Kato, A Curioni-Fontecedro, A Sacher, A Spira, SS Ramalingam, T Takahashi, B Besse, A Anderson, A Ang, Q Tran, O Mather, H Henary, G Ngarmchamnanrith, G Friberg, V Velcheti, R Govindan	06/24/2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy	JM Sands, SJ Mandrekar, D Kozono, GR Oxnard, SL Hillman, DA Wigle, R Govindan, J Carlisle, J Gray, JK Salama, L Raez, A Ganti, N Foster, S Malik, J Bradley, K Kelly, SS Ramalingam, TE Stinchcombe	06/01/2021
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	CE Steuer, OA Jegede, SE Dahlberg, HA Wakelee, SM Keller, WJ Tester, DR Gandara, SL Graziano, AA Adjei, CA Butts, SS Ramalingam, JH Schiller	06/01/2021
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. The oncologist	JM Varlotto, Z Sun, B Ky, J Upshaw, SI Katz, TJ Fitzgerald, H Wakelee, M Diehn, DA Mankoff, C Lovely, C Belani, K Oettel, G Masters, S Ramalingam, NA Pennell	06/01/2021
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical lung cancer	SN Waqar, MW Redman, SM Arnold, FR Hirsch, PC Mack, LH Schwartz, DR Gandara, TE Stinchcombe, NB Leighl, SS Ramalingam, SH Tanna, RS Raddin, K Minichiello, JD Bradley, K Kelly, RS Herbst, VA Papadimitrakopoulou	05/01/2021
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical lung cancer	TK Owonikoko, MW Redman, LA Byers, FR Hirsch, PC Mack, LH Schwartz, JD Bradley, TE Stinchcombe, NB Leighl, T Al Baghdadi, P Lara, J Miao, K Kelly, SS Ramalingam, RS Herbst, V Papadimitrakopoulou, DR Gandara	05/01/2021
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). JTO clinical and research reports	SA Khan, Z Sun, S Dahlberg, J Malhotra, R Keresztes, C Ikpeazu, P Ma, SS Ramalingam, R Pillai	05/01/2021
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	TK Owonikoko, B Dwivedi, Z Chen, C Zhang, B Barwick, V Ernani, G Zhang, M Gilbert-Ross, J Carlisle, FR Khuri, WJ Curran, AA Ivanov, H Fu, S Lonial, SS Ramalingam, SY Sun, EK Waller, GL Sica	03/01/2021
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Targeted oncology	Y Cheng, Y He, W Li, HL Zhang, Q Zhou, B Wang, C Liu, A Walding, M Saggese, X Huang, M Fan, J Wang, SS Ramalingam	03/01/2021
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research	MD Hellmann, PA Jänne, M Opyrchal, N Hafez, LE Raez, DI Gabrilovich, F Wang, JB Trepel, MJ Lee, A Yuno, S Lee, S Brouwer, S Sankoh, L Wang, D Tamang, EV Schmidt, ML Meyers, SS Ramalingam, E Shum, P Ordentlich	02/15/2021
Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget	J Koo, X Wang, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	02/02/2021
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414). JTO clinical and research reports	RN Pillai, SS Ramalingam, M Thayu, P Lorenzini, DA Alvarez Arias, C Moy, N Hutnick, R Knoblauch, H Feng, C Kane, L Horn, M Reck, S Ponce	02/01/2021
Co-Occurrence Conundrum: Brain Metastases from Lung Adenocarcinoma, Radiation Necrosis, and Gliosarcoma. Case reports in oncology	DC Qian, BD Weinberg, SG Neill, AL Goodman, JJ Olson, AD Voloschin, SS Ramalingam, HG Shu	01/01/2021
Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. PloS one	L Huang, R Bommireddy, LE Munoz, RN Guin, C Wei, A Ruggieri, AP Menon, X Li, M Shanmugam, TK Owonikoko, SS Ramalingam, P Selvaraj	01/01/2021
Discovery of Small Molecule Bak Activator for Lung Cancer Therapy. Theranostics	D Park, ASM Anisuzzaman, AT Magis, G Chen, M Xie, G Zhang, M Behera, GL Sica, SS Ramalingam, TK Owonikoko, X Deng	01/01/2021
Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. Theranostics	S Zhang, Z Chen, P Shi, S Fan, Y He, Q Wang, Y Li, SS Ramalingam, TK Owonikoko, SY Sun	01/01/2021
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	TF Burns, H Borghaei, SS Ramalingam, TS Mok, S Peters	12/10/2020
Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer. Cancer	B Nazha, S Goyal, Z Chen, A Engelhart, JW Carlisle, TJ Beardslee, H Gill, L Odikadze, Y Liu, MK Mishra, SS Ramalingam, TK Owonikoko	12/01/2020
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. Journal for immunotherapy of cancer	S Pakkala, K Higgins, Z Chen, G Sica, C Steuer, C Zhang, G Zhang, S Wang, MS Hossain, B Nazha, T Beardslee, FR Khuri, W Curran, S Lonial, EK Waller, S Ramalingam, TK Owonikoko	12/01/2020
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. Lung cancer (Amsterdam, Netherlands)	J Gu, L Qian, G Zhang, NP Mahajan, TK Owonikoko, SS Ramalingam, SY Sun	12/01/2020
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. The Lancet. Oncology	MW Redman, VA Papadimitrakopoulou, K Minichiello, FR Hirsch, PC Mack, LH Schwartz, E Vokes, S Ramalingam, N Leighl, J Bradley, J Miao, J Moon, L Highleyman, C Miwa, ML LeBlanc, S Malik, VA Miller, EV Sigal, S Adam, D Wholley, C Sigman, B Smolich, CD Blanke, K Kelly, DR Gandara, RS Herbst	12/01/2020
Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck. Clinical cancer research : an official journal of the American Association for Cancer Research	DM Shin, S Nannapaneni, MR Patel, Q Shi, Y Liu, Z Chen, AY Chen, MW El-Deiry, JJ Beitler, CE Steuer, SM Roser, AM Klein, TK Owonikoko, SS Ramalingam, FR Khuri, ZG Chen, NF Saba	11/15/2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Annals of oncology : official journal of the European Society for Medical Oncology	VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn, A Delmonte, SS Ramalingam, SW Kim, FA Shepherd, J Laskin, Y He, H Akamatsu, WSME Theelen, WC Su, T John, M Sebastian, H Mann, M Miranda, G Laus, Y Rukazenkov, YL Wu	11/01/2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clinical lung cancer	JD Patel, JW Lee, DP Carbone, H Wagner, A Shanker, MTP de Aquino, L Horn, ML Johnson, DE Gerber, JJ Liu, MS Das, MA Al-Nsour, CSR Dakhil, S Ramalingam, JH Schiller	11/01/2020
Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SJ Rice, V Hyland, M Behera, SS Ramalingam, P Bunn, CP Belani	11/01/2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British journal of cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	10/01/2020
Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. Cancer medicine	LE Steffen McLouth, F Zhao, TK Owonikoko, JL Feliciano, NA Mohindra, SE Dahlberg, JL Wade, G Srkalovic, BW Lash, JW Leach, TA Leal, C Aggarwal, D Cella, SS Ramalingam, LI Wagner	10/01/2020
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? Translational lung cancer research	CE Steuer, SS Ramalingam	10/01/2020
KRAS^G12C Inhibition with Sotorasib in Advanced Solid Tumors. The New England journal of medicine	DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, GS Falchook, TJ Price, A Sacher, CS Denlinger, YJ Bang, GK Dy, JC Krauss, Y Kuboki, JC Kuo, AL Coveler, K Park, TW Kim, F Barlesi, PN Munster, SS Ramalingam, TF Burns, F Meric-Bernstam, H Henary, J Ngang, G Ngarmchamnanrith, J Kim, BE Houk, J Canon, JR Lipford, G Friberg, P Lito, R Govindan, BT Li	09/24/2020
The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	MP Smeltzer, MW Wynes, S Lantuejoul, R Soo, SS Ramalingam, M Varella-Garcia, M Meadows Taylor, K Richeimer, K Wood, KE Howell, ML Dalurzo, E Felip, G Hollenbeck, K Kerr, ES Kim, C Mathias, J Pacheco, P Postmus, C Powell, M Tsuboi, II Wistuba, HA Wakelee, CP Belani, GV Scagliotti, FR Hirsch	09/01/2020
RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC. JTO clinical and research reports	BE Osta, SS Ramalingam	09/01/2020
MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. Cancer	J Gu, W Yao, P Shi, G Zhang, TK Owonikoko, SS Ramalingam, SY Sun	08/15/2020
Double immune checkpoint blockade in advanced NSCLC. Critical reviews in oncology/hematology	A Mariniello, S Novello, GV Scagliotti, SS Ramalingam	08/01/2020
Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. Cancer	B Pedro, M Rupji, B Dwivedi, J Kowalski, JM Konen, TK Owonikoko, SS Ramalingam, PM Vertino, AI Marcus	07/01/2020
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	AC Dingemans, RA Soo, AR Jazieh, SJ Rice, YT Kim, LLS Teo, GW Warren, SY Xiao, EF Smit, JG Aerts, SH Yoon, G Veronesi, F De Cobelli, SS Ramalingam, MC Garassino, MW Wynes, M Behera, J Haanen, S Lu, S Peters, MJ Ahn, GV Scagliotti, AA Adjei, CP Belani	07/01/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, C Wu, WB Harris, M Akce, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri	06/01/2020
Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis. The oncologist	M Behera, CE Steuer, Y Liu, F Fernandez, C Fu, KA Higgins, TW Gillespie, S Pakkala, RN Pillai, S Force, CP Belani, FR Khuri, WJ Curran, SS Ramalingam	06/01/2020
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. Molecular cancer	K Xu, D Park, AT Magis, J Zhang, W Zhou, GL Sica, SS Ramalingam, WJ Curran, X Deng	05/20/2020
Osimertinib in EGFR-Mutated Advanced NSCLC. Reply. The New England journal of medicine	SS Ramalingam, JC Soria	05/07/2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology	GR Oxnard, JC Yang, H Yu, SW Kim, H Saka, L Horn, K Goto, Y Ohe, H Mann, KS Thress, MM Frigault, K Vishwanathan, D Ghiorghiu, SS Ramalingam, MJ Ahn	04/01/2020
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. Molecular oncology	H Zang, G Qian, J Arbiser, TK Owonikoko, SS Ramalingam, S Fan, SY Sun	04/01/2020
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Cancer	Y Li, H Zang, G Qian, TK Owonikoko, SR Ramalingam, SY Sun	03/15/2020
Reply to N. Hanna et al and L. Xie et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, SE Dahlberg	03/01/2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. The oncologist	MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, A Speak, C Lewis, H Collins, HT Kissick, BC Carthon, M Akce, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master	03/01/2020
Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer. Reply. The New England journal of medicine	MD Hellmann, SS Ramalingam	02/27/2020
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RN Pillai, DA Fennell, V Kovcin, TE Ciuleanu, R Ramlau, D Kowalski, M Schenker, I Yalcin, F Teofilovici, VM Vukovic, SS Ramalingam	02/20/2020
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer	DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master, MA Bilen	02/01/2020
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer	VA Papadimitrakopoulou, JY Han, MJ Ahn, SS Ramalingam, A Delmonte, TC Hsia, J Laskin, SW Kim, Y He, CM Tsai, T Hida, M Maemondo, T Kato, S Jenkins, S Patel, X Huang, G Laus, A Markovets, KS Thress, YL Wu, T Mok	01/15/2020
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. The New England journal of medicine	SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, C Zhou, T Reungwetwattana, Y Cheng, B Chewaskulyong, R Shah, M Cobo, KH Lee, P Cheema, M Tiseo, T John, MC Lin, F Imamura, T Kurata, A Todd, R Hodge, M Saggese, Y Rukazenkov, JC Soria	01/02/2020
The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. American journal of cancer research	D Yu, Y Li, KD Sun, J Gu, Z Chen, TK Owonikoko, SS Ramalingam, SY Sun	01/01/2020
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer	H Zang, G Qian, D Zong, S Fan, TK Owonikoko, SS Ramalingam, SY Sun	01/01/2020
Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer. Clinical and translational science	K Vishwanathan, M Cantarini, K So, E Masson, J Fetterolf, SS Ramalingam, RD Harvey	01/01/2020
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	H Brown, J Vansteenkiste, K Nakagawa, M Cobo, T John, C Barker, A Kohlmann, A Todd, M Saggese, J Chmielecki, A Markovets, M Scott, SS Ramalingam	01/01/2020
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands)	DE Gerber, DR Camidge, D Morgensztern, J Cetnar, RJ Kelly, SS Ramalingam, DR Spigel, W Jeong, PP Scaglioni, S Zhang, M Li, DT Weaver, L Vaikus, M Keegan, JC Horobin, TF Burns	01/01/2020
Mcl-1 Interacts with Akt to Promote Lung Cancer Progression. Cancer research	G Chen, D Park, AT Magis, M Behera, SS Ramalingam, TK Owonikoko, GL Sica, K Ye, C Zhang, Z Chen, WJ Curran, X Deng	12/15/2019
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer chemotherapy and pharmacology	LJ Appleman, JH Beumer, Y Jiang, Y Lin, F Ding, S Puhalla, L Swartz, TK Owonikoko, R Donald Harvey, R Stoller, DP Petro, HA Tawbi, A Argiris, S Strychor, M Pouquet, B Kiesel, AP Chen, D Gandara, CP Belani, E Chu, SS Ramalingam	12/01/2019
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational new drugs	DJ Martini, Y Liu, JM Shabto, C Lewis, MR Kline, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, VA Master, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, MA Bilen	12/01/2019
Improving outcomes for brain metastases in EGFR mutated NSCLC. Translational lung cancer research	JW Carlisle, SS Ramalingam	12/01/2019
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine	MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, E Carcereny Costa, K Park, A Alexandru, L Lupinacci, E de la Mora Jimenez, H Sakai, I Albert, A Vergnenegre, S Peters, K Syrigos, F Barlesi, M Reck, H Borghaei, JR Brahmer, KJ O'Byrne, WJ Geese, P Bhagavatheeswaran, SK Rabindran, RS Kasinathan, FE Nathan, SS Ramalingam	11/21/2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	JE Gray, I Okamoto, V Sriuranpong, J Vansteenkiste, F Imamura, JS Lee, YK Pang, M Cobo, K Kasahara, Y Cheng, N Nogami, EK Cho, WC Su, G Zhang, X Huang, X Li-Sucholeiki, B Lentrichia, S Dearden, S Jenkins, M Saggese, Y Rukazenkov, SS Ramalingam	11/15/2019
Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. Clinical lung cancer	S Tian, X Zhang, R Jiang, RN Pillai, TK Owonikoko, CE Steuer, NF Saba, S Pakkala, PR Patel, CP Belani, FR Khuri, WJ Curran, SS Ramalingam, M Behera, KA Higgins	11/01/2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, JP Eder, AS Balmanoukian, C Aggarwal, L Horn, A Patnaik, M Gubens, SS Ramalingam, E Felip, JW Goldman, C Scalzo, E Jensen, DA Kush, R Hui	10/01/2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. The Lancet. Oncology	SJ Antonia, H Borghaei, SS Ramalingam, L Horn, J De Castro Carpeño, A Pluzanski, MA Burgio, M Garassino, LQM Chow, S Gettinger, L Crinò, D Planchard, C Butts, A Drilon, J Wojcik-Tomaszewska, GA Otterson, S Agrawal, A Li, JR Penrod, J Brahmer	10/01/2019
Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, SE Dahlberg, CP Belani, JN Saltzman, NA Pennell, GS Nambudiri, JC McCann, JD Winegarden, MA Kassem, MK Mohamed, JM Rothman, AP Lyss, L Horn, TE Stinchcombe, JH Schiller	09/10/2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC cancer	MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, H Kissick, BC Carthon, WL Shaib, OB Alese, CE Steuer, C Wu, DH Lawson, R Kudchadkar, VA Master, B El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey	08/29/2019
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation. Oncogene	L Deng, G Qian, S Zhang, H Zheng, S Fan, GB Lesinski, TK Owonikoko, SS Ramalingam, SY Sun	08/01/2019
Acetylation regulates ribonucleotide reductase activity and cancer cell growth. Nature communications	G Chen, Y Luo, K Warncke, Y Sun, DS Yu, H Fu, M Behera, SS Ramalingam, PW Doetsch, DM Duong, M Lammers, WJ Curran, X Deng	07/19/2019
A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer. Cancer	HS Gill, SS Ramalingam	07/01/2019
DNA-PKc deficiency drives pre-malignant transformation by reducing DNA repair capacity in concert with reprogramming the epigenome in human bronchial epithelial cells. DNA repair	I Teneng, MA Picchi, S Leng, CP Dagucon, S Ramalingam, CS Tellez, SA Belinsky	07/01/2019
Clinical prognostic model for older patients with advanced non-small cell lung cancer. Journal of geriatric oncology	AK Ganti, X Wang, TE Stinchcombe, Y Wang, J Bradley, HJ Cohen, K Kelly, R Paulus, SS Ramalingam, EE Vokes, H Pang	07/01/2019
Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head & neck	A Mohamed, B Twardy, MA Zordok, K Ashraf, A Alkhoder, K Schrapp, C Steuer, Z Chen, S Pakkala, R Pillai, J Trad Wadsworth, K Higgins, JJ Beitler, SS Ramalingam, TK Owonikoko, FR Khuri, DM Shin, M Behera, NF Saba	05/01/2019
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	B El Osta, M Behera, S Kim, LD Berry, G Sica, RN Pillai, TK Owonikoko, MG Kris, BE Johnson, DJ Kwiatkowski, LM Sholl, DL Aisner, PA Bunn, FR Khuri, SS Ramalingam	05/01/2019
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. The Journal of pharmacology and experimental therapeutics	E Grande, RD Harvey, B You, JF Batlle, H Galbraith, J Sarantopoulos, SS Ramalingam, H Mann, K So, M Johnson, K Vishwanathan	05/01/2019
The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. Translational oncology	P Shi, S Zhang, L Zhu, G Qian, H Ren, SS Ramalingam, M Chen, SY Sun	05/01/2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, H Borghaei, J Jolivet, L Horn, M Mates, J Brahmer, I Rabinowitz, PS Reddy, J Chesney, J Orcutt, DR Spigel, M Reck, KJ O'Byrne, L Paz-Ares, W Hu, K Zerba, X Li, B Lestini, WJ Geese, JD Szustakowski, G Green, H Chang, SS Ramalingam	04/20/2019
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy. Molecular cancer	K Xu, D Park, AT Magis, J Zhang, W Zhou, GL Sica, SS Ramalingam, WJ Curran, X Deng	04/10/2019
Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. American journal of clinical oncology	NF Saba, S Force, C Staley, F Fernandez, F Willingham, A Pickens, K Cardona, Z Chen, L Goff, D Cardin, E Lambright, J Nesbitt, A Krasinskas, K Higgins, RD Harvey, T Owonikoko, SS Ramalingam, DM Shin, JJ Beitler, BF El-Rayes, S Salaria, W El-Rifai, J Landry, AB Chakravarthy	04/01/2019
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	D Planchard, MJ Boyer, JS Lee, A Dechaphunkul, PK Cheema, T Takahashi, JE Gray, M Tiseo, SS Ramalingam, A Todd, A McKeown, Y Rukazenkov, Y Ohe	04/01/2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. The Lancet. Respiratory medicine	NB Leighl, MD Hellmann, R Hui, E Carcereny, E Felip, MJ Ahn, JP Eder, AS Balmanoukian, C Aggarwal, L Horn, A Patnaik, M Gubens, SS Ramalingam, GM Lubiniecki, J Zhang, B Piperdi, EB Garon	04/01/2019
Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer	MJ Ahn, CM Tsai, FA Shepherd, L Bazhenova, LV Sequist, T Hida, JCH Yang, SS Ramalingam, T Mitsudomi, PA Jänne, H Mann, M Cantarini, G Goss	03/15/2019
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future oncology (London, England)	JW Carlisle, SS Ramalingam	03/01/2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of oncology : official journal of the European Society for Medical Oncology	S Peters, U Dafni, M Boyer, D De Ruysscher, C Faivre-Finn, E Felip, P Garrido, N Girard, M Guckenberger, J Haanen, C Le Pechoux, F Mornex, M Ozsahin, L Paz-Ares, D Planchard, D Raben, S Ramalingam, M Reck, E Smit, R Stahel, A Stenzinger, C Swanton, S Vallone, MC Garassino	02/01/2019
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SE Schild, W Fan, TE Stinchcombe, EE Vokes, SS Ramalingam, JD Bradley, K Kelly, HH Pang, X Wang	02/01/2019
A banner year for immunotherapy and targeted therapy. Nature reviews. Clinical oncology	JW Carlisle, SS Ramalingam	02/01/2019
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	TK Owonikoko, SE Dahlberg, GL Sica, LI Wagner, JL Wade, G Srkalovic, BW Lash, JW Leach, TB Leal, C Aggarwal, SS Ramalingam	01/20/2019
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer	MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, VA Master, SS Ramalingam, TK Owonikoko, RD Harvey	01/01/2019
Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity. Cancer journal (Sudbury, Mass.)	VV Sukhatme, SS Ramalingam, R Ahmed, VP Sukhatme	01/01/2019
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Japanese journal of clinical oncology	Y Ohe, F Imamura, N Nogami, I Okamoto, T Kurata, T Kato, S Sugawara, SS Ramalingam, H Uchida, R Hodge, SL Vowler, A Walding, K Nakagawa	01/01/2019
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	BC Cho, B Chewaskulyong, KH Lee, A Dechaphunkul, V Sriuranpong, F Imamura, N Nogami, T Kurata, I Okamoto, C Zhou, Y Cheng, EK Cho, PJ Voon, JS Lee, H Mann, M Saggese, T Reungwetwattana, SS Ramalingam, Y Ohe	01/01/2019
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). The Lancet. Respiratory medicine	NK Altorki, X Wang, D Wigle, L Gu, G Darling, AS Ashrafi, R Landrenau, D Miller, M Liberman, DR Jones, R Keenan, M Conti, G Wright, LJ Veit, SS Ramalingam, M Kamel, HI Pass, JD Mitchell, T Stinchcombe, E Vokes, LJ Kohman	12/01/2018
Radiation Therapy Is Associated With an Increased Incidence of Cardiac Events in Patients with Small Cell Lung Cancer. International journal of radiation oncology, biology, physics	MJ Ferris, R Jiang, M Behera, SS Ramalingam, WJ Curran, KA Higgins	10/01/2018
Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. Cancer	RH Press, C Zhang, RJ Cassidy, MJ Ferris, J Zhong, CE Steuer, RN Pillai, TK Owonikoko, S Kahn, SS Ramalingam, PR Patel, WJ Curran, HG Shu, GL Sica, KA Higgins	09/01/2018
Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. Clinical lung cancer	ND Shukla, AA Salahudeen, GA Taylor, SS Ramalingam, EE Vokes, GD Goss, RH Decker, K Kelly, GV Scagliotti, TS Mok, HA Wakelee	09/01/2018
Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. Lung cancer (Amsterdam, Netherlands)	M Tessema, MR Rossi, MA Picchi, CM Yingling, Y Lin, SS Ramalingam, SA Belinsky	09/01/2018
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	T Reungwetwattana, K Nakagawa, BC Cho, M Cobo, EK Cho, A Bertolini, S Bohnet, C Zhou, KH Lee, N Nogami, I Okamoto, N Leighl, R Hodge, A McKeown, AP Brown, Y Rukazenkov, SS Ramalingam, J Vansteenkiste	08/28/2018
Personalized therapy for lung cancer: striking a moving target. JCI insight	S Pakkala, SS Ramalingam	08/09/2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology	PD Bonomi, D Gandara, FR Hirsch, KM Kerr, C Obasaju, L Paz-Ares, C Bellomo, JD Bradley, PA Bunn, M Culligan, JR Jett, ES Kim, CJ Langer, RB Natale, S Novello, M Pérol, SS Ramalingam, M Reck, CH Reynolds, EF Smit, MA Socinski, DR Spigel, JF Vansteenkiste, H Wakelee, N Thatcher	08/01/2018
Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SE Schild, HH Pang, W Fan, TE Stinchcombe, EE Vokes, SS Ramalingam, JD Bradley, K Kelly, X Wang	08/01/2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clinical lung cancer	FR Hirsch, KM Kerr, PA Bunn, ES Kim, C Obasaju, M Pérol, P Bonomi, JD Bradley, D Gandara, JR Jett, CJ Langer, RB Natale, S Novello, L Paz-Ares, SS Ramalingam, M Reck, CH Reynolds, EF Smit, MA Socinski, DR Spigel, TE Stinchcombe, JF Vansteenkiste, H Wakelee, N Thatcher	07/01/2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. The New England journal of medicine	MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, C Audigier-Valette, E Minenza, H Linardou, S Burgers, P Salman, H Borghaei, SS Ramalingam, J Brahmer, M Reck, KJ O'Byrne, WJ Geese, G Green, H Chang, J Szustakowski, P Bhagavatheeswaran, D Healey, Y Fu, F Nathan, L Paz-Ares	05/31/2018
Overexpression of the base excision repair NTHL1 glycosylase causes genomic instability and early cellular hallmarks of cancer. Nucleic acids research	KL Limpose, KS Trego, Z Li, SW Leung, AH Sarker, JA Shah, SS Ramalingam, EM Werner, WS Dynan, PK Cooper, AH Corbett, PW Doetsch	05/18/2018
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. Clinical lung cancer	SS Ramalingam, M Pérol, M Reck, RD Kowalyszyn, O Gautschi, M Kimmich, EK Cho, G Czyzewicz, A Grigorescu, N Karaseva, S Dakhil, P Lee, A Zimmerman, A Sashegyi, E Alexandris, GC Carter, KB Winfree, EB Garon	05/01/2018
Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams. Chest	S Murgu, R Rabito, G Lasko, C Jackson, M Mino-Kenudson, DS Ettinger, SS Ramalingam, ES Edell	04/01/2018
Throwing More Cold Water on Heat Shock Protein 90 Inhibitors in NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	RN Pillai, SS Ramalingam	04/01/2018
Osimertinib in EGFR Mutation-Positive Advanced NSCLC. The New England journal of medicine	JC Soria, SS Ramalingam	03/29/2018
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	GP Kalemkerian, N Narula, EB Kennedy, WA Biermann, J Donington, NB Leighl, M Lew, J Pantelas, SS Ramalingam, M Reck, A Saqi, M Simoff, N Singh, B Sundaram	03/20/2018
Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, JC Yang, CK Lee, T Kurata, DW Kim, T John, N Nogami, Y Ohe, H Mann, Y Rukazenkov, S Ghiorghiu, D Stetson, A Markovets, JC Barrett, KS Thress, PA Jänne	03/20/2018
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). Clinical cancer research : an official journal of the American Association for Cancer Research	DL Aisner, LM Sholl, LD Berry, MR Rossi, H Chen, J Fujimoto, AL Moreira, SS Ramalingam, LC Villaruz, GA Otterson, E Haura, K Politi, B Glisson, J Cetnar, EB Garon, J Schiller, SN Waqar, LV Sequist, J Brahmer, Y Shyr, K Kugler, II Wistuba, BE Johnson, JD Minna, MG Kris, PA Bunn, DJ Kwiatkowski	03/01/2018
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? Journal of clinical oncology : official journal of the American Society of Clinical Oncology	CE Steuer, SS Ramalingam	03/01/2018
Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer	RJ Cassidy, X Zhang, JM Switchenko, PR Patel, JW Shelton, S Tian, RH Nanda, CE Steuer, RN Pillai, TK Owonikoko, SS Ramalingam, FG Fernandez, SD Force, TW Gillespie, WJ Curran, KA Higgins	02/15/2018
Immunotherapy in previously treated non-small cell lung cancer (NSCLC). Journal of thoracic disease	TA Leal, SS Ramalingam	02/01/2018
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	MA Socinski, C Obasaju, D Gandara, FR Hirsch, P Bonomi, PA Bunn, ES Kim, CJ Langer, RB Natale, S Novello, L Paz-Ares, M Pérol, M Reck, SS Ramalingam, CH Reynolds, DR Spigel, H Wakelee, N Thatcher	02/01/2018
CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual review of medicine	M Hashimoto, AO Kamphorst, SJ Im, HT Kissick, RN Pillai, SS Ramalingam, K Araki, R Ahmed	01/29/2018
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer	RN Pillai, M Behera, TK Owonikoko, AO Kamphorst, S Pakkala, CP Belani, FR Khuri, R Ahmed, SS Ramalingam	01/15/2018
Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer	HI Assi, AO Kamphorst, NM Moukalled, SS Ramalingam	01/15/2018
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine	JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, KH Lee, A Dechaphunkul, F Imamura, N Nogami, T Kurata, I Okamoto, C Zhou, BC Cho, Y Cheng, EK Cho, PJ Voon, D Planchard, WC Su, JE Gray, SM Lee, R Hodge, M Marotti, Y Rukazenkov, SS Ramalingam	01/11/2018
Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy. The Journal of clinical investigation	G Chen, AT Magis, K Xu, D Park, DS Yu, TK Owonikoko, GL Sica, SW Satola, SS Ramalingam, WJ Curran, PW Doetsch, X Deng	01/02/2018
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Annals of oncology : official journal of the European Society for Medical Oncology	J Remon, CE Steuer, SS Ramalingam, E Felip	01/01/2018
Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. Oncology	TK Owonikoko, AK Busari, S Kim, Z Chen, A Akintayo, C Lewis, BC Carthon, OB Alese, BF El-Rayes, SS Ramalingam, RD Harvey	01/01/2018
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). Annals of oncology : official journal of the European Society for Medical Oncology	A Argiris, JW Lee, J Stevenson, MG Sulecki, V Hugec, NW Choong, JN Saltzman, W Song, RM Hansen, TL Evans, SS Ramalingam, JH Schiller	12/01/2017
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology	HA Wakelee, SE Dahlberg, SM Keller, WJ Tester, DR Gandara, SL Graziano, AA Adjei, NB Leighl, SC Aisner, JM Rothman, JD Patel, MD Sborov, SR McDermott, R Perez-Soler, AM Traynor, C Butts, T Evans, A Shafqat, AE Chapman, SS Kasbari, L Horn, SS Ramalingam, JH Schiller	12/01/2017
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer	RN Pillai, M Behera, LD Berry, MR Rossi, MG Kris, BE Johnson, PA Bunn, SS Ramalingam, FR Khuri	11/01/2017
Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. Cancer prevention research (Philadelphia, Pa.)	SA Belinsky, S Leng, G Wu, CL Thomas, MA Picchi, SJ Lee, S Aisner, S Ramalingam, FR Khuri, DD Karp	11/01/2017
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clinical cancer research : an official journal of the American Association for Cancer Research	P Shi, YT Oh, L Deng, G Zhang, G Qian, S Zhang, H Ren, G Wu, B Legendre, E Anderson, SS Ramalingam, TK Owonikoko, M Chen, SY Sun	11/01/2017
Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. Clinical lung cancer	AK Ganti, FR Hirsch, MW Wynes, A Ravelo, SS Ramalingam, R Ionescu-Ittu, I Pivneva, H Borghaei	11/01/2017
Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis. Clinical lung cancer	HZ Ahmed, Y Liu, K O'Connell, MZ Ahmed, RJ Cassidy, TW Gillespie, P Patel, RN Pillai, M Behera, CE Steuer, TK Owonikoko, SS Ramalingam, WJ Curran, KA Higgins	11/01/2017
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	KA Higgins, RN Pillai, Z Chen, S Tian, C Zhang, P Patel, S Pakkala, J Shelton, SD Force, FG Fernandez, CE Steuer, TK Owonikoko, SS Ramalingam, JD Bradley, WJ Curran	11/01/2017
Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. Cancer	RJ Cassidy, X Zhang, PR Patel, JW Shelton, CE Escott, GL Sica, MR Rossi, CE Hill, CE Steuer, RN Pillai, SS Ramalingam, TK Owonikoko, M Behera, SD Force, FG Fernandez, WJ Curran, KA Higgins	10/01/2017
Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	EM Gore, C Hu, AY Sun, DF Grimm, SS Ramalingam, NE Dunlap, KA Higgins, M Werner-Wasik, AM Allen, P Iyengar, GMM Videtic, RK Hales, RC McGarry, JJ Urbanic, AT Pu, CA Johnstone, VW Stieber, R Paulus, JD Bradley	10/01/2017
Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	S Garcia, A Bisen, J Yan, XJ Xie, S Ramalingam, JH Schiller, DH Johnson, DE Gerber	10/01/2017
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. Cancer	KB Naik, Y Liu, M Goodman, TW Gillespie, A Pickens, SD Force, CE Steuer, TK Owonikoko, SS Ramalingam, K Higgins, JJ Beitler, DM Shin, FF Willingham, B El-Rayes, JC Landry, FG Fernandez, NF Saba	09/15/2017
Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget	S Leng, G Wu, DM Klinge, CL Thomas, E Casas, MA Picchi, CA Stidley, SJ Lee, S Aisner, JM Siegfried, S Ramalingam, FR Khuri, DD Karp, SA Belinsky	09/08/2017
Stereotactic Body Radiotherapy for Early-stage Non-small-cell Lung Cancer in Patients 80 Years and Older: A Multi-center Analysis. Clinical lung cancer	RJ Cassidy, PR Patel, X Zhang, RH Press, JM Switchenko, RN Pillai, TK Owonikoko, SS Ramalingam, FG Fernandez, SD Force, WJ Curran, KA Higgins	09/01/2017
Assays for PD-L1 Expression: Do All Roads Lead to Rome? JAMA oncology	GL Sica, SS Ramalingam	08/01/2017
Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review. JAMA oncology	CE Steuer, M Behera, V Ernani, KA Higgins, NF Saba, DM Shin, S Pakkala, RN Pillai, TK Owonikoko, WJ Curran, CP Belani, FR Khuri, SS Ramalingam	08/01/2017
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	S Jenkins, JC Yang, SS Ramalingam, K Yu, S Patel, S Weston, R Hodge, M Cantarini, PA Jänne, T Mitsudomi, GD Goss	07/01/2017
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	M Reck, N Blais, E Juhasz, V Gorbunova, CM Jones, L Urban, S Orlov, F Barlesi, E Kio, U Keilholz, Q Qin, J Qian, C Nickner, J Dziubinski, H Xiong, RK Mittapalli, M Dunbar, P Ansell, L He, M McKee, V Giranda, SS Ramalingam	07/01/2017
Modulation of Bax and mTOR for Cancer Therapeutics. Cancer research	R Li, C Ding, J Zhang, M Xie, D Park, Y Ding, G Chen, G Zhang, M Gilbert-Ross, W Zhou, AI Marcus, SY Sun, ZG Chen, GL Sica, SS Ramalingam, AT Magis, H Fu, FR Khuri, WJ Curran, TK Owonikoko, DM Shin, J Zhou, X Deng	06/01/2017
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America	AO Kamphorst, RN Pillai, S Yang, TH Nasti, RS Akondy, A Wieland, GL Sica, K Yu, L Koenig, NT Patel, M Behera, H Wu, M McCausland, Z Chen, C Zhang, FR Khuri, TK Owonikoko, R Ahmed, SS Ramalingam	05/09/2017
Discussing molecular testing in oncology care: Comparing patient and physician information preferences. Cancer	APM Pinheiro, RH Pocock, JM Switchenko, MD Dixon, WL Shaib, SS Ramalingam, RD Pentz	05/01/2017
Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. Clinical lung cancer	CE Steuer, M Behera, Y Liu, C Fu, TW Gillespie, NF Saba, DM Shin, RN Pillai, S Pakkala, TK Owonikoko, FR Khuri, SS Ramalingam	05/01/2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JC Yang, MJ Ahn, DW Kim, SS Ramalingam, LV Sequist, WC Su, SW Kim, JH Kim, D Planchard, E Felip, F Blackhall, D Haggstrom, K Yoh, S Novello, K Gold, T Hirashima, CC Lin, H Mann, M Cantarini, S Ghiorghiu, PA Jänne	04/20/2017
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	SS Ramalingam, N Blais, J Mazieres, M Reck, CM Jones, E Juhasz, L Urban, S Orlov, F Barlesi, E Kio, U Keiholz, Q Qin, J Qian, C Nickner, J Dziubinski, H Xiong, P Ansell, M McKee, V Giranda, V Gorbunova	04/15/2017
Using Metaphors to Explain Molecular Testing to Cancer Patients. The oncologist	AP Pinheiro, RH Pocock, MD Dixon, WL Shaib, SS Ramalingam, RD Pentz	04/01/2017
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science (New York, N.Y.)	AO Kamphorst, A Wieland, T Nasti, S Yang, R Zhang, DL Barber, BT Konieczny, CZ Daugherty, L Koenig, K Yu, GL Sica, AH Sharpe, GJ Freeman, BR Blazar, LA Turka, TK Owonikoko, RN Pillai, SS Ramalingam, K Araki, R Ahmed	03/31/2017
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI insight	M Gilbert-Ross, J Konen, J Koo, J Shupe, BS Robinson, WG Wiles, C Huang, WD Martin, M Behera, GH Smith, CE Hill, MR Rossi, GL Sica, M Rupji, Z Chen, J Kowalski, AL Kasinski, SS Ramalingam, H Fu, FR Khuri, W Zhou, AI Marcus	03/09/2017
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. The New England journal of medicine	TS Mok, Y-L Wu, M-J Ahn, MC Garassino, HR Kim, SS Ramalingam, FA Shepherd, Y He, H Akamatsu, WS Theelen, CK Lee, M Sebastian, A Templeton, H Mann, M Marotti, S Ghiorghiu, VA Papadimitrakopoulou	02/16/2017
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm. Hematology/oncology clinics of North America	S Pakkala, SS Ramalingam	02/01/2017
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer immunology, immunotherapy : CII	TK Owonikoko, M Kumar, S Yang, AO Kamphorst, RN Pillai, R Akondy, V Nautiyal, MS Chatwal, WM Book, A Sahu, GL Sica, R Ahmed, SS Ramalingam	01/01/2017
Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clinical lung cancer	AA Salahudeen, MI Patel, P Baas, WJ Curran, JD Bradley, DR Gandara, GD Goss, TS Mok, SS Ramalingam, EE Vokes, SM Malik, HA Wakelee	01/01/2017
National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. International journal of radiation oncology, biology, physics	KA Higgins, K O'Connell, Y Liu, TW Gillespie, MW McDonald, RN Pillai, KR Patel, PR Patel, CG Robinson, CB Simone, TK Owonikoko, CP Belani, FR Khuri, WJ Curran, SS Ramalingam, M Behera	01/01/2017
American Society of Clinical Oncology Policy Brief: FDA's Regulation of Electronic Nicotine Delivery Systems and Tobacco Products. Journal of oncology practice	JK Merrill, AJ Alberg, JR Goffin, SS Ramalingam, VN Simmons, GW Warren	01/01/2017
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. Oncology	M Evans, Y Liu, C Chen, C Steuer, R Cassidy, J Landry, K Higgins, JJ Beitler, F Willingham, TK Owonikoko, SS Ramalingam, DM Shin, NK Jegadeesh, B El-Rayes, F Fernandez, AM Krasinskas, T Gillespie, NF Saba	01/01/2017
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	CJ Langer, C Obasaju, P Bunn, P Bonomi, D Gandara, FR Hirsch, ES Kim, RB Natale, S Novello, L Paz-Ares, M Pérol, M Reck, SS Ramalingam, CH Reynolds, MA Socinski, DR Spigel, H Wakelee, C Mayo, N Thatcher	12/01/2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. The Lancet. Oncology	JW Neal, SE Dahlberg, HA Wakelee, SC Aisner, M Bowden, Y Huang, DP Carbone, GJ Gerstner, RE Lerner, JL Rubin, TK Owonikoko, PJ Stella, PD Steen, AA Khalid, SS Ramalingam	12/01/2016
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	HH Pang, X Wang, TE Stinchcombe, ML Wong, P Cheng, AK Ganti, DJ Sargent, Y Zhang, C Hu, SJ Mandrekar, MW Redman, JB Manola, RL Schilsky, HJ Cohen, JD Bradley, AA Adjei, D Gandara, SS Ramalingam, EE Vokes	11/20/2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. Cancer	AK Nooka, M Behera, S Lonial, MD Dixon, SS Ramalingam, RD Pentz	10/15/2016
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. American journal of clinical oncology	CJ Langer, MA Socinski, JD Patel, AB Sandler, JH Schiller, L Leon, SJ Hazard, SS Ramalingam	10/01/2016
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer letters	P Shi, YT Oh, G Zhang, W Yao, P Yue, Y Li, R Kanteti, J Riehm, R Salgia, TK Owonikoko, SS Ramalingam, M Chen, SY Sun	10/01/2016
Metastatic Lung Cancer: Emerging Therapeutic Strategies. Seminars in respiratory and critical care medicine	S Saif Ur Rehman, SS Ramalingam	10/01/2016
Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base. Clinical lung cancer	N Jegadeesh, Y Liu, T Gillespie, F Fernandez, S Ramalingam, J Mikell, J Lipscomb, WJ Curran, KA Higgins	09/01/2016
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. Clinical lung cancer	M Behera, TK Owonikoko, AA Gal, CE Steuer, S Kim, RN Pillai, FR Khuri, SS Ramalingam, GL Sica	09/01/2016
Clinicopathologic Features of Advanced Squamous NSCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	MA Socinski, C Obasaju, D Gandara, FR Hirsch, P Bonomi, P Bunn, ES Kim, CJ Langer, RB Natale, S Novello, L Paz-Ares, M Pérol, M Reck, SS Ramalingam, CH Reynolds, DR Spigel, TE Stinchcombe, H Wakelee, C Mayo, N Thatcher	09/01/2016
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer	CP Belani, SE Dahlberg, CM Rudin, M Fleisher, HX Chen, N Takebe, MR Velasco, WJ Tester, K Sturtz, CL Hann, JC Shanks, M Monga, SS Ramalingam, JH Schiller	08/01/2016
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of oncology : official journal of the European Society for Medical Oncology	SS Ramalingam, K O'Byrne, M Boyer, T Mok, PA Jänne, H Zhang, J Liang, I Taylor, EI Sbar, L Paz-Ares	07/01/2016
International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	F de Marinis, E Bria, F Ciardiello, L Crinò, JY Douillard, F Griesinger, D Lambrechts, M Perol, SS Ramalingam, EF Smit, C Gridelli	07/01/2016
EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer discovery	K Konduri, JN Gallant, YK Chae, FJ Giles, BJ Gitlitz, K Gowen, E Ichihara, TK Owonikoko, V Peddareddigari, SS Ramalingam, SK Reddy, B Eaby-Sandy, T Vavalà, A Whiteley, H Chen, Y Yan, JH Sheehan, J Meiler, D Morosini, JS Ross, PJ Stephens, VA Miller, SM Ali, CM Lovly	06/01/2016
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer. Journal of translational medicine	TK Owonikoko, G Zhang, HS Kim, RM Stinson, R Bechara, C Zhang, Z Chen, NF Saba, S Pakkala, R Pillai, X Deng, SY Sun, MR Rossi, GL Sica, SS Ramalingam, FR Khuri	05/03/2016
Scientific Advances in Lung Cancer 2015. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	AS Tsao, GV Scagliotti, PA Bunn, DP Carbone, GW Warren, C Bai, HJ de Koning, AU Yousaf-Khan, A McWilliams, MS Tsao, PS Adusumilli, R Rami-Porta, H Asamura, PE Van Schil, GE Darling, SS Ramalingam, DR Gomez, KE Rosenzweig, S Zimmermann, S Peters, SH Ignatius Ou, T Reungwetwattana, PA Jänne, TS Mok, HA Wakelee, R Pirker, J Mazières, JR Brahmer, Y Zhou, RS Herbst, VA Papadimitrakopoulou, MW Redman, MW Wynes, DR Gandara, RJ Kelly, FR Hirsch, HI Pass	05/01/2016
Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. The oncologist	AJ Olszanski, DC Smith, LH Camacho, J Thompson, SS Ramalingam, RD Harvey, L Campos, D Ferry, S Tang, L Gao, H Safran	04/01/2016
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of oncology : official journal of the European Society for Medical Oncology	SS Ramalingam, K O'Byrne, M Boyer, T Mok, PA Jänne, H Zhang, J Liang, I Taylor, EI Sbar, L Paz-Ares	03/01/2016
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer	CE Steuer, M Behera, L Berry, S Kim, M Rossi, G Sica, TK Owonikoko, BE Johnson, MG Kris, PA Bunn, FR Khuri, EB Garon, SS Ramalingam	03/01/2016
Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives. Current opinion in oncology	S Pakkala, SS Ramalingam	03/01/2016
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. The Journal of molecular diagnostics : JMD	KE Fisher, L Zhang, J Wang, GH Smith, S Newman, TM Schneider, RN Pillai, RR Kudchadkar, TK Owonikoko, SS Ramalingam, DH Lawson, KA Delman, BF El-Rayes, MM Wilson, HC Sullivan, AS Morrison, S Balci, NV Adsay, AA Gal, GL Sica, DF Saxe, KP Mann, CE Hill, FR Khuri, MR Rossi	03/01/2016
Small-Cell Lung Cancer: New Directions for Systemic Therapy. Journal of oncology practice	SS Ramalingam	02/01/2016
Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer	M Behera, C Ragin, S Kim, RN Pillai, Z Chen, CE Steuer, NF Saba, CP Belani, FR Khuri, SS Ramalingam, TK Owonikoko	01/01/2016
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	R Govindan, SJ Mandrekar, DE Gerber, GR Oxnard, SE Dahlberg, J Chaft, S Malik, M Mooney, JS Abrams, PA Jänne, DR Gandara, SS Ramalingam, EE Vokes	12/15/2015
Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer	RH Nanda, Y Liu, TW Gillespie, JL Mikell, SS Ramalingam, FG Fernandez, WJ Curran, J Lipscomb, KA Higgins	12/01/2015
Analysis of liver-directed therapies in U.S. cancer patients. Current oncology (Toronto, Ont.)	OB Alese, S Kim, Z Chen, SS Ramalingam, TK Owonikoko, BF El-Rayes	12/01/2015
Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost. JAMA oncology	DA Goldstein, Q Chen, T Ayer, DH Howard, J Lipscomb, SS Ramalingam, FR Khuri, CR Flowers	12/01/2015
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	CM Rudin, N Ismaila, CL Hann, N Malhotra, B Movsas, K Norris, MC Pietanza, SS Ramalingam, AT Turrisi, G Giaccone	12/01/2015
Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	OV Khullar, Y Liu, T Gillespie, KA Higgins, S Ramalingam, J Lipscomb, FG Fernandez	11/01/2015
Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib. Lung cancer (Amsterdam, Netherlands)	EM McKeegan, PJ Ansell, G Davis, S Chan, RK Chandran, SH Gawel, BL Dowell, A Bhathena, A Chakravartty, MD McKee, JL Ricker, DM Carlson, SS Ramalingam, V Devanarayan	11/01/2015
Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular aspects of medicine	CE Steuer, SS Ramalingam	11/01/2015
Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	H Chow, MJ Edelman, G Giaccone, SS Ramalingam, TA Quill, AD Bowser, J Mortimer, W Guerra, LA Beckett, HL West, PN Lara, DR Gandara	10/01/2015
Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors. Seminars in oncology	G Miles, J Rae, SS Ramalingam, J Pfeifer	10/01/2015
Early detection of lung cancer in China: The immediate imperative. Cancer	S Veeraraghavan, SS Ramalingam, FR Khuri	09/01/2015
Lung cancer in China: The new frontier? Cancer	SS Ramalingam, FR Khuri	09/01/2015
Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base. Journal of the American College of Surgeons	JN Melvan, MS Sancheti, T Gillespie, DC Nickleach, Y Liu, K Higgins, S Ramalingam, J Lipscomb, FG Fernandez	08/01/2015
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	M Behera, RN Pillai, TK Owonikoko, S Kim, C Steuer, Z Chen, NF Saba, CP Belani, FR Khuri, SS Ramalingam	08/01/2015
Time to divest from tobacco-funded research. Cancer	FR Khuri, SS Ramalingam	07/15/2015
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer	NH Hanna, SE Dahlberg, JM Kolesar, C Aggarwal, FR Hirsch, SS Ramalingam, JH Schiller	07/01/2015
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	NR Foster, LA Renfro, SE Schild, MW Redman, XF Wang, SE Dahlberg, K Ding, PA Bradbury, SS Ramalingam, DR Gandara, T Shibata, N Saijo, EE Vokes, AA Adjei, SJ Mandrekar	07/01/2015
A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung cancer (Amsterdam, Netherlands)	TK Owonikoko, SE Dahlberg, SA Khan, DE Gerber, J Dowell, RA Moss, CP Belani, CL Hann, C Aggarwal, SS Ramalingam	07/01/2015
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer cell	B Han, D Park, R Li, M Xie, TK Owonikoko, G Zhang, GL Sica, C Ding, J Zhou, AT Magis, ZG Chen, DM Shin, SS Ramalingam, FR Khuri, WJ Curran, X Deng	06/08/2015
Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis. Oral oncology	LJ Joseph, M Goodman, K Higgins, R Pilai, SS Ramalingam, K Magliocca, MR Patel, M El-Deiry, JT Wadsworth, TK Owonikoko, JJ Beitler, FR Khuri, DM Shin, NF Saba	06/01/2015
Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. World journal of oncology	OB Alese, S Kim, Z Chen, W Shaib, CA Staley, SS Ramalingam, TK Owonikoko, BF El-Rayes	06/01/2015
Innovative Clinical Trials: The LUNG-MAP Study. Clinical pharmacology and therapeutics	CE Steuer, V Papadimitrakopoulou, RS Herbst, MW Redman, FR Hirsch, PC Mack, SS Ramalingam, DR Gandara	05/01/2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. The New England journal of medicine	PA Jänne, JC Yang, DW Kim, D Planchard, Y Ohe, SS Ramalingam, MJ Ahn, SW Kim, WC Su, L Horn, D Haggstrom, E Felip, JH Kim, P Frewer, M Cantarini, KH Brown, PA Dickinson, S Ghiorghiu, M Ranson	04/30/2015
GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget	J Koo, X Wang, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	04/20/2015
The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer	CE Steuer, FR Khuri, SS Ramalingam	04/15/2015
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, SS Ramalingam, DL Miller, SD Force, GL Sica, J Mendel, Z Chen, A Rogatko, M Tighiouart, RD Harvey, S Kim, NF Saba, A Pickens, M Behera, RW Fu, MR Rossi, WF Auffermann, WE Torres, R Bechara, X Deng, SY Sun, H Fu, AA Gal, FR Khuri	04/15/2015
Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung cancer (Amsterdam, Netherlands)	CE Steuer, M Behera, S Kim, N Patel, Z Chen, R Pillai, NF Saba, DM Shin, TK Owonikoko, FR Khuri, SS Ramalingam	04/01/2015
Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	CE Steuer, M Behera, S Kim, Z Chen, NF Saba, RN Pillai, TK Owonikoko, FR Khuri, SS Ramalingam	03/01/2015
Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	JL Mikell, TW Gillespie, WA Hall, DC Nickleach, Y Liu, J Lipscomb, SS Ramalingam, RS Rajpara, SD Force, FG Fernandez, TK Owonikoko, RN Pillai, FR Khuri, WJ Curran, KA Higgins	03/01/2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. The Lancet. Oncology	NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, L Horn, H Lena, E Minenza, B Mennecier, GA Otterson, LT Campos, DR Gandara, BP Levy, SG Nair, G Zalcman, J Wolf, PJ Souquet, E Baldini, F Cappuzzo, C Chouaid, A Dowlati, R Sanborn, A Lopez-Chavez, C Grohe, RM Huber, CT Harbison, C Baudelet, BJ Lestini, SS Ramalingam	03/01/2015
Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	TK Owonikoko, SS Ramalingam	02/20/2015
Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, M Shtivelband, RA Soo, CH Barrios, A Makhson, JG Segalla, KB Pittman, P Kolman, JR Pereira, G Srkalovic, CP Belani, R Axelrod, TK Owonikoko, Q Qin, J Qian, EM McKeegan, V Devanarayan, MD McKee, JL Ricker, DM Carlson, VA Gorbunova	02/10/2015
Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base. Journal of the American College of Surgeons	OV Khullar, T Gillespie, DC Nickleach, Y Liu, K Higgins, S Ramalingam, J Lipscomb, FG Fernandez	02/01/2015
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	D Morgensztern, MJ Campo, SE Dahlberg, RC Doebele, E Garon, DE Gerber, SB Goldberg, PS Hammerman, RS Heist, T Hensing, L Horn, SS Ramalingam, CM Rudin, R Salgia, LV Sequist, AT Shaw, GR Simon, N Somaiah, DR Spigel, J Wrangle, D Johnson, RS Herbst, P Bunn, R Govindan	01/01/2015
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells. Oncoscience	PJ Webber, C Park, M Qui, SS Ramalingam, FR Khuri, H Fu, Y Du	01/01/2015
Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer	NF Saba, SJ Hurwitz, K Magliocca, S Kim, TK Owonikoko, D Harvey, SS Ramalingam, Z Chen, J Rogerio, J Mendel, SA Kono, C Lewis, AY Chen, K Higgins, M El-Deiry, T Wadsworth, JJ Beitler, DM Shin, SY Sun, FR Khuri	12/15/2014
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer medicine	TK Owonikoko, G Zhang, X Deng, MR Rossi, JM Switchenko, GH Doho, Z Chen, S Kim, S Strychor, SM Christner, J Beumer, C Li, P Yue, A Chen, GL Sica, SS Ramalingam, J Kowalski, FR Khuri, SY Sun	12/01/2014
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. Lung cancer (Amsterdam, Netherlands)	C Langer, A Ravelo, SJ Hazard, A Guerin, R Ionescu-Ittu, D Latremouille-Viau, EQ Wu, S Ramalingam	12/01/2014
Necitumumab: a new therapeutic option for squamous cell lung cancer? Translational lung cancer research	RN Pillai, SS Ramalingam	12/01/2014
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NB Leighl, N Rekhtman, WA Biermann, J Huang, M Mino-Kenudson, SS Ramalingam, H West, S Whitlock, MR Somerfield	11/10/2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet. Oncology	SS Ramalingam, PA Jänne, T Mok, K O'Byrne, MJ Boyer, J Von Pawel, A Pluzanski, M Shtivelband, LI Docampo, J Bennouna, H Zhang, JQ Liang, JP Doherty, I Taylor, CB Mather, Z Goldberg, J O'Connell, L Paz-Ares	11/01/2014
Small-molecule Bax agonists for cancer therapy. Nature communications	M Xin, R Li, M Xie, D Park, TK Owonikoko, GL Sica, PE Corsino, J Zhou, C Ding, MA White, AT Magis, SS Ramalingam, WJ Curran, FR Khuri, X Deng	09/17/2014
Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. Oral oncology	M Behera, TK Owonikoko, S Kim, Z Chen, K Higgins, SS Ramalingam, DM Shin, FR Khuri, JJ Beitler, NF Saba	09/01/2014
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). Cancer chemotherapy and pharmacology	RN Pillai, J Aisner, SE Dahlberg, JS Rogers, RS DiPaola, S Aisner, SS Ramalingam, JH Schiller	07/01/2014
Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis. Cell death and differentiation	B Wang, M Xie, R Li, TK Owonikoko, SS Ramalingam, FR Khuri, WJ Curran, Y Wang, X Deng	07/01/2014
Second-generation ALK inhibitors: filling the non "MET" gap. Cancer discovery	SS Ramalingam, FR Khuri	06/01/2014
HPV-associated lung cancers: an international pooled analysis. Carcinogenesis	C Ragin, M Obikoya-Malomo, S Kim, Z Chen, R Flores-Obando, D Gibbs, C Koriyama, F Aguayo, J Koshiol, NE Caporaso, GE Carpagnano, M Ciotti, H Dosaka-Akita, M Fukayama, A Goto, DA Spandidos, V Gorgoulis, DA Heideman, RA van Boerdonk, K Hiroshima, R Iwakawa, NG Kastrinakis, I Kinoshita, S Akiba, MT Landi, H Eugene Liu, JL Wang, R Mehra, FR Khuri, WT Lim, TK Owonikoko, S Ramalingam, E Sarchianaki, K Syrjanen, MS Tsao, J Sykes, SW Hee, J Yokota, A Zaravinos, E Taioli	06/01/2014
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer	H Kang, TW Gillespie, M Goodman, SA Brodie, M Brandes, M Ribeiro, SS Ramalingam, DM Shin, FR Khuri, JC Brandes	05/01/2014
Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. Asia-Pacific journal of clinical oncology	M Boyer, MS Tsao, P Jänne, S Ramalingam, S Pitman Lowenthal, M Alam	04/01/2014
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer prevention research (Philadelphia, Pa.)	NF Saba, SJ Hurwitz, SA Kono, CS Yang, Y Zhao, Z Chen, G Sica, S Müller, R Moreno-Williams, M Lewis, W Grist, AY Chen, CE Moore, TK Owonikoko, S Ramalingam, JJ Beitler, S Nannapaneni, HJ Shin, JR Grandis, FR Khuri, ZG Chen, DM Shin	03/01/2014
Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer prevention research (Philadelphia, Pa.)	SA Brodie, G Li, A El-Kommos, H Kang, SS Ramalingam, M Behera, K Gandhi, J Kowalski, GL Sica, FR Khuri, PM Vertino, JC Brandes	03/01/2014
Heat shock protein 90 inhibitors in non-small-cell lung cancer. Current opinion in oncology	RN Pillai, SS Ramalingam	03/01/2014
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck. Head and neck pathology	NF Saba, KR Magliocca, S Kim, S Muller, Z Chen, TK Owonikoko, NJ Sarlis, C Eggers, V Phelan, WJ Grist, AY Chen, SS Ramalingam, ZG Chen, JJ Beitler, DM Shin, FR Khuri, AI Marcus	03/01/2014
Advances in the diagnosis and treatment of non-small cell lung cancer. Molecular cancer therapeutics	RN Pillai, SS Ramalingam	03/01/2014
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer chemotherapy and pharmacology	TK Owonikoko, J Aisner, XV Wang, SE Dahlberg, EH Rubin, SS Ramalingam, M Gounder, PG Rausch, RS Axelrod, JH Schiller	01/01/2014
Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase. Cancer research	M Xie, Y Yen, TK Owonikoko, SS Ramalingam, FR Khuri, WJ Curran, PW Doetsch, X Deng	01/01/2014
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals of oncology : official journal of the European Society for Medical Oncology	S Ramalingam, J Crawford, A Chang, C Manegold, R Perez-Soler, JY Douillard, N Thatcher, F Barlesi, T Owonikoko, Y Wang, P Pultar, J Zhu, R Malik, G Giaccone	11/01/2013
Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung cancer. Cancer	BR Eaton, S Kim, DM Marcus, R Prabhu, Z Chen, SS Ramalingam, WJ Curran, KA Higgins	11/01/2013
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Molecular cancer therapeutics	R Li, Z Hu, SY Sun, ZG Chen, TK Owonikoko, GL Sica, SS Ramalingam, WJ Curran, FR Khuri, X Deng	10/01/2013
Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. Cancer research	D Park, AT Magis, R Li, TK Owonikoko, GL Sica, SY Sun, SS Ramalingam, FR Khuri, WJ Curran, X Deng	09/01/2013
Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SE Dahlberg, JH Schiller, PB Bonomi, AB Sandler, JR Brahmer, SS Ramalingam, DH Johnson	09/01/2013
A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands)	SS Ramalingam, A Kotsakis, AA Tarhini, DE Heron, R Smith, D Friedland, DP Petro, LE Raez, JR Brahmer, JS Greenberger, S Dacic, P Hershberger, RJ Landreneau, JD Luketich, CP Belani, A Argiris	09/01/2013
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	MA Socinski, J Goldman, I El-Hariry, M Koczywas, V Vukovic, L Horn, E Paschold, R Salgia, H West, LV Sequist, P Bonomi, J Brahmer, LC Chen, A Sandler, CP Belani, T Webb, H Harper, M Huberman, S Ramalingam, KK Wong, F Teofilovici, W Guo, GI Shapiro	06/01/2013
Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. The Journal of biological chemistry	Y Li, X Wang, P Yue, H Tao, SS Ramalingam, TK Owonikoko, X Deng, Y Wang, H Fu, FR Khuri, SY Sun	05/10/2013
Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer	TK Owonikoko, MS Hossain, C Bhimani, Z Chen, S Kim, SS Ramalingam, SY Sun, DM Shin, EK Waller, FR Khuri	04/15/2013
Reply to M.C. Garassino et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, J O'Connell, JQ Liang	03/20/2013
CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research	RN Pillai, SA Brodie, GL Sica, Y Shaojin, G Li, DC Nickleach, L Yuan, VA Varma, D Bonta, JG Herman, MV Brock, MJ Ribeiro, SS Ramalingam, TK Owonikoko, FR Khuri, JC Brandes	03/15/2013
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. British journal of cancer	RD Harvey, TK Owonikoko, CM Lewis, A Akintayo, Z Chen, M Tighiouart, SS Ramalingam, MP Fanucchi, P Nadella, A Rogatko, DM Shin, B El-Rayes, FR Khuri, JS Kauh	03/05/2013
Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables. Clinical lung cancer	M Behera, JJ Heine, GL Sica, EE Fowler, H Tran, RW Fu, AA Gal, R Hermann, W Mayfield, FR Khuri, TK Owonikoko, SS Ramalingam	03/01/2013
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, TK Owonikoko, M Behera, J Subramanian, NF Saba, SA Kono, AA Gal, G Sica, RD Harvey, Z Chen, CM Klass, DM Shin, H Fu, SY Sun, R Govindan, FR Khuri	03/01/2013
Inhibition of insulin-like growth factor receptor: end of a targeted therapy? Translational lung cancer research	RN Pillai, SS Ramalingam	02/01/2013
Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PloS one	R Marullo, E Werner, N Degtyareva, B Moore, G Altavilla, SS Ramalingam, PW Doetsch	01/01/2013
Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. The oncologist	TK Owonikoko, C Ragin, Z Chen, S Kim, M Behera, JC Brandes, NF Saba, R Pentz, SS Ramalingam, FR Khuri	01/01/2013
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer letters	H Ren, M Chen, P Yue, H Tao, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	12/28/2012
Hsp90 inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	RN Pillai, SS Ramalingam	12/01/2012
c-Myc suppression of DNA double-strand break repair. Neoplasia (New York, N.Y.)	Z Li, TK Owonikoko, SY Sun, SS Ramalingam, PW Doetsch, ZQ Xiao, FR Khuri, WJ Curran, X Deng	12/01/2012
Hypogonadism related to crizotinib therapy: implications for patient care. Cancer	SS Ramalingam, AT Shaw	11/01/2012
Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist. Journal of oncology practice	M Dillmon, JM Goldberg, SS Ramalingam, RJ Mayer, P Loehrer, C Van Poznak	11/01/2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, F Blackhall, M Krzakowski, CH Barrios, K Park, I Bover, D Seog Heo, R Rosell, DC Talbot, R Frank, SP Letrent, A Ruiz-Garcia, I Taylor, JQ Liang, AK Campbell, J O'Connell, M Boyer	09/20/2012
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer	CL Ellington, M Goodman, SA Kono, W Grist, T Wadsworth, AY Chen, T Owonikoko, S Ramalingam, DM Shin, FR Khuri, JJ Beitler, NF Saba	09/15/2012
Lung cancer with translocation in the anaplastic lymphoma kinase gene: a disease within a disease. Cancer	SS Ramalingam, FR Khuri	09/15/2012
Treatment of lung cancer. Radiologic clinics of North America	SM Gadgeel, SS Ramalingam, GP Kalemkerian	09/01/2012
Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. Lung cancer (Amsterdam, Netherlands)	M Behera, TK Owonikoko, Z Chen, SA Kono, FR Khuri, CP Belani, SS Ramalingam	08/01/2012
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer chemotherapy and pharmacology	AO Aregbe, EA Sherer, MJ Egorin, HI Scher, DB Solit, RK Ramanathan, S Ramalingam, CP Belani, PS Ivy, RR Bies	07/01/2012
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research	CM Rudin, CL Hann, EB Garon, M Ribeiro de Oliveira, PD Bonomi, DR Camidge, Q Chu, G Giaccone, D Khaira, SS Ramalingam, MR Ranson, C Dive, EM McKeegan, BJ Chyla, BL Dowell, A Chakravartty, CE Nolan, N Rudersdorf, TA Busman, MH Mabry, AP Krivoshik, RA Humerickhouse, GI Shapiro, L Gandhi	06/01/2012
A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	TK Owonikoko, M Behera, Z Chen, C Bhimani, WJ Curran, FR Khuri, SS Ramalingam	05/01/2012
The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. Current oncology reports	RN Pillai, SS Ramalingam	04/01/2012
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer biology & therapy	Y Li, S Fan, J Koo, P Yue, ZG Chen, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	03/01/2012
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer chemotherapy and pharmacology	J Chao, TW Synold, RJ Morgan, C Kunos, J Longmate, HJ Lenz, D Lim, S Shibata, V Chung, RG Stoller, CP Belani, DR Gandara, M McNamara, BJ Gitlitz, DH Lau, SS Ramalingam, A Davies, I Espinoza-Delgado, EM Newman, Y Yen	03/01/2012
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer chemotherapy and pharmacology	CL O'Bryant, P Haluska, L Rosen, RK Ramanathan, B Venugopal, S Leong, R Boinpally, A Franke, K Witt, J Evans, C Belani, S Gail Eckhardt, S Ramalingam	03/01/2012
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	BJ Gitlitz, DD Tsao-Wei, S Groshen, A Davies, M Koczywas, CP Belani, A Argiris, S Ramalingam, EE Vokes, M Edelman, P Hoffman, MS Ballas, SV Liu, DR Gandara	03/01/2012
Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases. The Journal of biological chemistry	Q Qi, K He, MH Yoo, CB Chan, X Liu, Z Zhang, JJ Olson, G Xiao, L Wang, H Mao, H Fu, H Tao, SS Ramalingam, SY Sun, PS Mischel, K Ye	02/24/2012
Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Journal of clinical pharmacology	H Wu, RK Ramanathan, BA Zamboni, S Strychor, S Ramalingam, RP Edwards, DM Friedland, RG Stoller, CP Belani, LJ Maruca, YJ Bang, WC Zamboni	02/01/2012
Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy. Cancer	S Pakkala, Z Chen, D Rimland, TK Owonikoko, C Gunthel, JR Brandes, NR Saba, DM Shin, WJ Curran, FR Khuri, SS Ramalingam	01/01/2012
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. International journal of nanomedicine	H Wu, RK Ramanathan, BA Zamboni, S Strychor, S Ramalingam, RP Edwards, DM Friedland, RG Stoller, CP Belani, LJ Maruca, YJ Bang, WC Zamboni	01/01/2012
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Investigational new drugs	EI Heath, P Lorusso, SS Ramalingam, A Awada, MJ Egorin, T Besse-Hamer, F Cardoso, M Valdivieso, T Has, L Alland, X Zhou, CP Belani	12/01/2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, DR Spigel, D Chen, MB Steins, JA Engelman, CP Schneider, S Novello, WE Eberhardt, L Crino, K Habben, L Liu, PA Jänne, CM Brownstein, M Reck	12/01/2011
Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data. Biomedical engineering online	M Behera, EE Fowler, TK Owonikoko, WH Land, W Mayfield, Z Chen, FR Khuri, SS Ramalingam, JJ Heine	11/08/2011
Histone deacetylase inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam	11/01/2011
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, AM Davies, J Longmate, MJ Edelman, PN Lara, EE Vokes, M Villalona-Calero, B Gitlitz, K Reckamp, R Salgia, JJ Wright, CP Belani, DR Gandara	10/01/2011
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer biology & therapy	CX Xu, L Zhao, P Yue, G Fang, H Tao, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	09/15/2011
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer	J Kauh, C Chanel-Vos, D Escuin, MP Fanucchi, RD Harvey, N Saba, DM Shin, A Gal, L Pan, M Kutner, SS Ramalingam, L Bender, A Marcus, P Giannakakou, FR Khuri	09/01/2011
Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression. Cancer research	L Dhandapani, P Yue, SS Ramalingam, FR Khuri, SY Sun	08/01/2011
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors. Journal of liposome research	WC Zamboni, LJ Maruca, S Strychor, BA Zamboni, S Ramalingam, RP Edwards, J Kim, Y Bang, H Lee, DM Friedland, RG Stoller, CP Belani, RK Ramanathan	06/01/2011
Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, JW Lee, CP Belani, SC Aisner, J Kolesar, C Howe, MR Velasco, JH Schiller	05/01/2011
A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer. Human gene therapy	AA Tarhini, CP Belani, JD Luketich, A Argiris, SS Ramalingam, W Gooding, A Pennathur, D Petro, K Kane, D Liggitt, T Championsmith, X Zhang, MW Epperly, JS Greenberger	03/01/2011
RNA binding protein CUGBP2/CELF2 mediates curcumin-induced mitotic catastrophe of pancreatic cancer cells. PloS one	D Subramaniam, S Ramalingam, DC Linehan, BK Dieckgraefe, RG Postier, CW Houchen, RA Jensen, S Anant	02/11/2011
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer chemotherapy and pharmacology	KD Holen, CP Belani, G Wilding, S Ramalingam, JL Volkman, RK Ramanathan, LS Vasist, CJ Bowen, JP Hodge, MM Dar, PT Ho	02/01/2011
Lung cancer: New biological insights and recent therapeutic advances. CA: a cancer journal for clinicians	SS Ramalingam, TK Owonikoko, FR Khuri	01/01/2011
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clinical lung cancer	PN Lara, J Longmate, K Reckamp, B Gitlitz, A Argiris, S Ramalingam, CP Belani, PC Mack, DH Lau, M Koczywas, JJ Wright, FA Shepherd, N Leighl, DR Gandara	01/01/2011
Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. Oncology	NF Saba, M Goodman, K Ward, C Flowers, S Ramalingam, T Owonikoko, A Chen, W Grist, T Wadsworth, JJ Beitler, FR Khuri, DM Shin	01/01/2011
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PloS one	CX Xu, Y Li, P Yue, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun	01/01/2011
Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam	12/01/2010
Lung cancer in HIV-positive patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	S Pakkala, SS Ramalingam	11/01/2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, S Kummar, J Sarantopoulos, S Shibata, P LoRusso, M Yerk, J Holleran, Y Lin, JH Beumer, RD Harvey, SP Ivy, CP Belani, MJ Egorin	10/10/2010
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer	SS Ramalingam, RD Harvey, N Saba, TK Owonikoko, J Kauh, DM Shin, SY Sun, S Strychor, M Tighiouart, MJ Egorin, H Fu, FR Khuri	08/15/2010
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, CP Belani, PC Mack, EE Vokes, J Longmate, R Govindan, M Koczywas, SP Ivy, DR Gandara	08/01/2010
What is the role of maintenance therapy in the treatment of non-small cell lung cancer? Therapeutic advances in medical oncology	Y Jiang, TK Owonikoko, SS Ramalingam, FR Khuri, CP Belani	07/01/2010
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer? The Lancet. Oncology	TE Stinchcombe, SS Ramalingam	06/01/2010
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, SS Ramalingam, CP Belani	05/01/2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RK Ramanathan, MJ Egorin, C Erlichman, SC Remick, SS Ramalingam, C Naret, JL Holleran, CJ TenEyck, SP Ivy, CP Belani	03/20/2010
Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer. Cancer	SS Ramalingam, J Foster, W Gooding, T Evans, M Sulecki, CP Belani	03/01/2010
Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. Current opinion in oncology	SS Ramalingam, CP Belani	03/01/2010
Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. International journal of cancer	TK Owonikoko, SS Ramalingam, B Kanterewicz, TE Balius, CP Belani, PA Hershberger	02/01/2010
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, ML Maitland, P Frankel, AE Argiris, M Koczywas, B Gitlitz, S Thomas, I Espinoza-Delgado, EE Vokes, DR Gandara, CP Belani	01/01/2010
Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. Seminars in oncology	S Harichand-Herdt, SS Ramalingam	12/01/2009
Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer	TS Mok, SS Ramalingam	11/15/2009
PI3 kinase, mTOR, and AKT pathways. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, FR Khuri	11/01/2009
Preoperative therapy for early-stage NSCLC: opportunities and challenges. Oncology (Williston Park, N.Y.)	TK Owonikoko, FR Khuri, SS Ramalingam	09/01/2009
Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer biology & therapy	S Fan, SS Ramalingam, J Kauh, Z Xu, FR Khuri, SY Sun	08/01/2009
Duration of chemotherapy for metastatic non-small-cell lung cancer: more may be better after all. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JH Schiller, SS Ramalingam	07/10/2009
The role of cetuximab in the management of non-small-cell lung cancer. Clinical lung cancer	TK Owonikoko, SY Sun, SS Ramalingam	07/01/2009
Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	R Camidge, L Gaspar, G Goss, K Kelly, S Ramalingam, K Reckamp, G Simon, M Tsao, HJ West, R Herbst, D Johnson, P Bunn, R Govindan	07/01/2009
Diallyl trisulfide selectively causes Bax- and Bak-mediated apoptosis in human lung cancer cells. Environmental and molecular mutagenesis	D Xiao, Y Zeng, ER Hahm, YA Kim, S Ramalingam, SV Singh	04/01/2009
The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. The oncologist	SS Ramalingam, FR Khuri	04/01/2009
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clinical lung cancer	S Pakkala, SS Ramalingam	03/01/2009
Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research	WC Zamboni, S Ramalingam, DM Friedland, RP Edwards, RG Stoller, S Strychor, L Maruca, BA Zamboni, CP Belani, RK Ramanathan	02/15/2009
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clinical therapeutics	K Venkatakrishnan, M Rader, RK Ramanathan, S Ramalingam, E Chen, W Riordan, W Trepicchio, M Cooper, M Karol, L von Moltke, R Neuwirth, M Egorin, G Chatta	01/01/2009
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, CP Belani, C Ruel, P Frankel, B Gitlitz, M Koczywas, I Espinoza-Delgado, D Gandara	01/01/2009
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer biology & therapy	X Wang, N Hawk, P Yue, J Kauh, SS Ramalingam, H Fu, FR Khuri, SY Sun	12/01/2008
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC). Current treatment options in oncology	TK Owonikoko, S Ramalingam	12/01/2008
Minimal progress, potential promise in small-cell lung cancer. Oncology (Williston Park, N.Y.)	T Owonikoko, S Ramalingam	11/30/2008
Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer	CP Belani, MT Schreeder, RG Steis, RA Guidice, TA Marsland, EH Butler, SS Ramalingam	11/01/2008
Recent advances in the treatment of malignant pleural mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	SS Ramalingam, CP Belani	09/01/2008
Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer	S Ramalingam, MC Perry, RV La Rocca, D Rinaldi, PS Gable, WJ Tester, CP Belani	08/01/2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research	SS Ramalingam, MJ Egorin, RK Ramanathan, SC Remick, RP Sikorski, TF Lagattuta, GS Chatta, DM Friedland, RG Stoller, DM Potter, SP Ivy, CP Belani	06/01/2008
Gene expression profiling of non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands)	S Singhal, D Miller, S Ramalingam, SY Sun	06/01/2008
Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. Clinical lung cancer	PN Lara, SS Ramalingam	05/01/2008
Management of a patient with stage IIIA (N2) NSCLC. Oncology (Williston Park, N.Y.)	K Carlson, BZ Fowler, DL Miller, A Gal, S Ramalingam	04/30/2008
Small cell lung cancer in elderly patients: a review. Journal of the National Comprehensive Cancer Network : JNCCN	TK Owonikoko, S Ramalingam	03/01/2008
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	S Ramalingam, J Forster, C Naret, T Evans, M Sulecki, H Lu, P Teegarden, MR Weber, CP Belani	03/01/2008
Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	CP Belani, S Ramalingam, MC Perry, RV LaRocca, D Rinaldi, PS Gable, WJ Tester	01/20/2008
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	SS Ramalingam, SE Dahlberg, CJ Langer, R Gray, CP Belani, JR Brahmer, AB Sandler, JH Schiller, DH Johnson	01/01/2008
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Seminars in thoracic and cardiovascular surgery	S Harichand-Herdt, SS Ramalingam	01/01/2008
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. The oncologist	S Ramalingam, C Belani	01/01/2008

Awards

As a physician scientist, Dr. Ramalingam has received numerous peer-reviewed grants from the National Cancer Institute. He is also the recipient of several awards including the James Eckman Award for Excellence in Teaching at Emory, ECOG-ACRIN Young Investigator Award and NCI Cancer Clinical Investigator Team Leadership Award. He has been consistently listed in Atlanta Magazine's annual "Top Doctors" issue since 2018.

Dr. Ramalingam has been named to the MilliPub Club, which recognizes current Emory University School of Medicine faculty who have published one or more individual papers throughout their careers that have garnered more than 1,000 citations.

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	01/29/2025	I highly recommend this doctor to others. He is not only good doctor but he is also very humble very good human being.
One star One star One star One star One star	11/27/2024	Dr. R and his staff are knowledgeable in his field. He is patient and takes all the time I need during my appointments. I'm confident that I am getting the very best care.
One star One star One star One star One star	08/23/2024	Caring and competent